

Improving malaria case management with artemisinin-based combination therapies and malaria rapid diagnostic tests in private medicine retail outlets in sub-Saharan Africa: a systematic review

Short title (max 100 characters): Improving malaria case management in retail outlets in sub-Saharan Africa: a systematic review

3 May 2023

Authors: Catherine Goodman^{1*}, Sarah Tougher¹, Terrissa Jing Shang¹, Theodoor Visser²

¹ Department for Global Health and Development. London School of Hygiene and Tropical Medicine, London, UK

² Clinton Health Access Initiative, Inc. (CHAI), Global Malaria, Boston, USA

* Corresponding author

Email: catherine.goodman@lshtm.ac.uk (CG)

1 Abstract

2

3 Private medicine retailers (PMRs) such as pharmacies and drug stores account for a substantial share
4 of treatment-seeking for fever and malaria, but there are widespread concerns about quality of care,
5 including inadequate access to malaria rapid diagnostic tests (RDTs) and artemisinin-based
6 combination therapies (ACTs). This review synthesizes evidence on the effectiveness of interventions
7 to improve malaria case management in PMRs in sub-Saharan Africa (PROSPERO
8 #2021:CRD42021253564). We included quantitative studies evaluating interventions supporting RDT
9 and/or ACT sales by PMR staff, with a historical or contemporaneous control group, and outcomes
10 related to care received. We searched Medline Ovid, Embase Ovid, Global Health Ovid, Econlit Ovid
11 and the Cochrane Library; unpublished studies were identified by contacting key informants. We
12 conducted a narrative synthesis by intervention category. We included 41 papers, relating to 34
13 studies. There was strong evidence that small and large-scale ACT subsidy programmes (without RDTs)
14 increased the market share of quality-assured ACT in PMRs, including among rural and poorer groups,
15 with increases of over 30 percentage points in most settings. Interventions to introduce or enhance
16 RDT use in PMRs led to RDT uptake among febrile clients of over two-thirds and dispensing according
17 to RDT result of over three quarters, though some studies had much poorer results. Introducing
18 Integrated Community Case Management (iCCM) was also effective in improving malaria case
19 management. However, there were no eligible studies on RDT or iCCM implementation at large scale.
20 There was limited evidence that PMR accreditation (without RDTs) increased ACT uptake. Key
21 evidence gaps include evaluations of RDTs and iCCM at large scale, evaluations of interventions
22 including use of digital technologies, and robust studies of accreditation and other broader PMR
23 interventions.

24 Introduction

25 Malaria remains a leading cause of the burden of disease in Africa, accounting for an estimated 228
26 million cases and 602 000 deaths in 2020, around 95% of global malaria cases and deaths [1]. The past
27 10-15 years have witnessed considerable progress in case management of malaria, particularly
28 through the introduction of highly effective artemisinin-based combination therapies (ACTs) as first-
29 line treatment, and the expansion of parasitological diagnosis. Since 2010 the World Health
30 Organisation (WHO) has recommended parasitological diagnosis for every suspected malaria case, as
31 clinical malaria is indistinguishable from the early stages of many other diseases, meaning that reliance
32 on clinical diagnosis alone leads to a substantial proportion of patients being treated with antimalarials
33 when their illness has a non-malarial cause [2]. The feasibility of parasitological diagnosis has also been
34 substantially enhanced by the introduction of malaria rapid diagnostic tests (RDTs) which are quick
35 (<20 min), accurate, simple to use, and relatively inexpensive [3].

36 While ACTs and RDTs have been widely adopted in public healthcare facilities across Africa [4],
37 coverage remains inadequate in the private sector, which accounts for a high proportion of treatment
38 seeking for malaria and fever. Among febrile children under 5 for whom care was sought, 30.8% sought
39 care in the private sector based on household surveys conducted between 2015-19 [1], and the
40 percent is likely higher in older age groups. Private sector use is particularly high in some of the highest
41 malaria burden countries in sub-Saharan Africa, accounting for over 50% of treatment seeking for sick
42 children in Nigeria, Uganda, and Tanzania [5]. The private sector includes private facilities (such as
43 clinics and hospitals) and private medicine retailers (PMRs). PMRs encompass both retail pharmacies
44 that should be staffed by someone with a pharmacy qualification, and drug shops with less qualified
45 staff, that are allowed to sell a more limited range of medicines, variously known as patent medicine
46 vendors, over-the-counter medicine sellers or dépôts de médicaments. In some settings, medicines
47 are also available through general stores, market stalls and hawkers. PMRs account for a substantial

48 share of private sector treatment seeking for fever, accounting for example for over 60% of private
49 sector visits for sick children in Tanzania, the Democratic Republic of Congo (DRC), and Nigeria [5].

50 There are widespread concerns about the quality of malaria case management received from PMRs.
51 Febrile patients treated through PMRs typically receive no parasitological diagnosis, as microscopy is
52 not feasible in retail settings and RDT availability is very patchy [6]. Although in most countries with
53 high private sector use some ACTs can legally be sold without a prescription in pharmacies and drug
54 stores [7], in practice, patients often purchase less effective antimalarials or no antimalarial treatment
55 [8]. In addition, there are concerns around the quality of ACTs [9], lack of referral to public sector
56 facilities, inappropriate use of antibiotics, and the failure to include malaria cases treated by PMRs in
57 national surveillance data [10].

58 A range of strategies have been developed to address these concerns. In the pre-ACT era, programmes
59 typically involved some combination of PMR training, job aids, pre-packaging of tablets, and social
60 marketing, with occasional use of accreditation and franchising [11]. With the introduction of ACTs,
61 which were initially substantially more expensive than more commonly used antimalarials such as
62 chloroquine, more radical action was taken to reduce ACT prices in the private sector. ACTs were
63 distributed with a significant subsidy with the intent of reducing retail prices for patients, and thus
64 increasing ACT demand and crowding out other, often less effective, antimalarials. ACT subsidies
65 began through small-scale pilots, but were then adopted on a massive scale under the Affordable
66 Medicine Facility-malaria (AMFm). The AMFm was established by the Global Fund to Fight AIDS,
67 Tuberculosis and Malaria, covering 7 African countries: Ghana, Kenya, Madagascar, Niger, Nigeria,
68 Uganda, and Tanzania from 2010-12 [12, 13]. It subsidised quality-assured ACTs, defined as those pre-
69 qualified by WHO or approved by Stringent Regulatory Authorities. Following this period, the Global
70 Fund continued private sector ACT subsidies through the private sector co-payment mechanism (CPM)
71 in six countries [8]. Unlike the AMFm which had earmarked funding, countries were required to
72 allocate funds to the CPM from their core Global Fund malaria grant.

73 In parallel, various groups began testing interventions to introduce RDTs in PMRs [14]. Other groups
74 focused more broadly on treatment of childhood illness, adapting Integrated Community Case
75 Management (iCCM) guidelines for the treatment of malaria, pneumonia and diarrhoea for drug
76 stores [15, 16]. A few countries, beginning with Tanzania, implemented large-scale accreditation
77 schemes for PMRs, including sales of subsidised ACTs [17].

78 More recent years have seen fewer large-scale PMR malaria interventions in sub-Saharan Africa, but
79 there is currently renewed interest in this topic among national and multilateral organizations [18,
80 19], reflecting the continued high treatment seeking rates in this sector. As no comprehensive, up-to-
81 date systematic review was identified on strategies to improve care of febrile patients by PMR, WHO
82 commissioned this review. The objective was to synthesize the evidence on the effect of interventions
83 relating to malaria case management on improving care received from PMRs in sub-Saharan Africa,
84 based on evaluations with a historical or contemporaneous control group. It updates the review by
85 Visser et al on RDT introduction in PMRs [14], while also broadening the scope to consider any
86 intervention relevant to malaria case management.

87

88 **Methods**

89 **Eligibility Criteria**

90 This systematic review followed the 2015 PRISMA-p guidelines and was registered on PROSPERO
91 (2021: CRD42021253564) where the protocol can be accessed.

92 We included studies conducted in sub-Saharan Africa only, reflecting the high malaria burden of many
93 of these countries. While there is considerable literature on malaria case management in PMRs from
94 outside Africa, particularly from the Greater Mekong Subregion [20], we focus on sub-Saharan Africa
95 given the substantial differences in malaria epidemiology and retail market structure between regions.

96 We included all published and unpublished randomized and non-randomized controlled trials, pre-
97 post designs with or without a control group, and time-series or repeated measure surveys, that
98 reported on an intervention to support the provision of RDTs and/or ACTs by PMR staff. We included
99 evaluations of both malaria-specific interventions and broader interventions that encompass ACTs or
100 RDTs. Studies that did not report on original research, such as opinion pieces and literature reviews,
101 were excluded, as were reports or conference abstracts with insufficient methodological detail.

102 We defined PMRs as pharmacies, drug stores and any other for-profit private sector retailer supplying
103 medicines. Studies that only reported on for-profit healthcare facilities such as clinics, health centers,
104 and hospitals, not-for-profit providers or community health workers were excluded. To be eligible,
105 studies must have reported on at least one of our primary outcomes, which comprised any
106 measurement of the effect of an intervention on ACT and RDT uptake, dispensing treatment according
107 to test results, referral on the basis of protocol, patient adherence to the treatment regimen, antibiotic
108 uptake, antimalarial quality, and health outcomes (further details provided below). These outcomes
109 were selected as they relate directly to the care received by users, as opposed to intermediate
110 outcomes such as staff knowledge, product availability or price.

111 We included studies where data were collected between January 2006 and March 2023. The time
112 frame was chosen because prior to 2006, PMR interventions did not involve ACTs or RDTs, and
113 therefore their findings are expected to be less applicable to the current context.

114 **Search Strategy**

115 A systematic literature search for published studies was conducted on March 10th, 2023, in Medline
116 Ovid, Embase Ovid, Global Health Ovid, Cochrane Library and Econlit Ovid. The search terms were
117 synonyms, related terms and MESH terms for five domains (i) 'malaria and fever' (ii) 'PMRs' (iii)
118 'diagnosis and treatment' (iv) 'antimalarials' and (v) 'Sub-Saharan Africa' (see full search strategy in S1
119 Table).

120 The search terms were strategically combined, and their performance tested by comparing a list of
121 pre-identified eligible papers to the search results. The results were then filtered by the time limit (Jan
122 2006-March 2023) and language (English and French). The results of the final searches were exported
123 into Covidence, and duplicates removed.

124 Covidence was used for independent screening by two authors (ST & TJS). Title and abstracts were
125 screened to identify papers that reported on interventions pertaining to ACT and/or RDT within the
126 private sector, with studies excluded that did not meet the study design criteria. For papers meeting
127 the screening criteria, a full-text review was conducted to determine eligibility. Discrepancies were
128 resolved by discussion and consultation with a third author (CG). Reference lists of all included studies
129 and of earlier related literature reviews [11, 14-16, 21-23] were examined to check for additional
130 papers not captured in the search.

131 Unpublished studies were identified by contacting researchers and practitioners in the field; a full-text
132 review was conducted independently by ST and CG to identify eligible studies.

133 Data extraction, outcomes, and quality assessment

134 We conducted a narrative synthesis rather than meta-analysis because of the high degree of
135 heterogeneity across studies in terms of their study design, outcomes, intervention and context. The
136 studies were classified into four broad intervention categories, and the intervention activities, data
137 collection methods, and primary outcomes extracted for each study.

138 Eligible studies were tabulated to document the direction, magnitude and significance of effects for
139 each reported primary outcome. The following primary outcomes were extracted and synthesized:

- 140 1. **ACT uptake:** The proportion of patients with a history of fever who received an ACT (or a
141 quality-assured ACT) (use), or the proportion of antimalarials dispensed that are ACT (or a
142 quality-assured ACT) (market share).
- 143 2. **RDT uptake:** The proportion of patients with a history of fever who received an RDT.

- 144 3. **Dispensing treatment according to test results:** Typically, the proportion of patients who
145 received no antimalarial after a negative RDT result and the proportion of patients who
146 received ACT after a positive RDT result (though there was some variation in definitions used).
- 147 4. **Referral:** The proportion of patients requiring referral by intervention protocol who were
148 appropriately referred; and the proportion of patients referred who completed the referral.
- 149 5. **Patient adherence:** The proportion of patients dispensed ACT who completed the full dose as
150 directed.
- 151 6. **Antibiotic uptake:** The proportion of patients with a history of fever that received an
152 antibiotic.
- 153 7. **Antimalarial quality:** The proportion of antimalarials purchased or sold that passed medicine
154 quality control tests.
- 155 8. **Health outcomes:** Any health-related outcomes including but not limited to mortality,
156 morbidity, recovery rates, further treatment-seeking, and post-treatment anemia.

157

158 The methodological quality of each study was assessed using an adjusted Downs and Black quality
159 assessment instrument that was developed to appraise the quality of quantitative studies [24]. After
160 testing various quality assessment tools, Downs and Black was chosen as the primary tool due to its
161 ability to capture the wide range of study designs in this review. Minor adjustments were made to the
162 tool to better assess the range of studies included in this review, including the addition of questions
163 from the Effective Public Health Practice Project quality assessment tool for quantitative studies,
164 Drummond's checklist for assessing economic evaluations, and the Newcastle-Ottawa Scale for
165 assessing the quality of nonrandomised studies in meta-analyses (S2 Table) [25-27]. The quality
166 assessment for each study was conducted by two authors independently. The results were used to
167 inform the narrative synthesis, with any concerns about specific studies noted in the results.

168 The results were synthesized within each intervention category. Factors such as context, background,
169 the difference in participants, variations in interventions, quality of evidence, and outcomes were
170 considered to understand the differences in direction and size of effect across studies.

171 Choice of data source reported

172 The choice of data source for outcomes such as RDT uptake and medicines dispensed can have an
173 important impact on study findings. Sources may include extracting data from registers or other
174 records that providers keep themselves (provider records), direct observation of provider activities by
175 research team staff present at the PMR, exit interviews with clients leaving a PMR, patient follow-up
176 surveys (where patients are telephoned or visited at home after their PMR visit), and cross-sectional
177 household and outlet surveys. The potential for a Hawthorne effect (where PMRs alter their behaviour
178 because they are being observed) or social desirability bias (where they record or state what they
179 believe are correct behaviours) are likely to be highest with provider records and direct observation,
180 followed by exit interviews and outlet surveys, but lower for patient follow-up surveys or household
181 surveys. However, the potential for recall bias is likely to be highest in household surveys, which may
182 also be more susceptible to confounding by contextual changes in the health system e.g. public sector
183 stockouts. To take account of this in the results we note the data source whenever we describe
184 studies. Where a study has more than one data source for a given indicator we generally present exit
185 interviews (rather than direct observation or household surveys).

186

187 Results

188 Study Selection

189 A total of 2598 records were identified through the database searches, plus 4 records identified
190 through other sources (Fig 1). After removing duplicates, 1466 records were screened by title and

191 abstract, and 168 full text records were assessed for eligibility. Of these 41 papers were included in
192 the review, relating to 34 distinct studies.

193 **Fig 1. PRISMA Flow Diagram**

194 The studies were categorised into four groups based on intervention content and breadth: (i)
195 introducing and enhancing ACT use (with no RDTs) (12 studies); (ii) introducing and enhancing RDT
196 use (15 studies); (iii) integrated community case management (iCCM) of malaria, pneumonia and
197 diarrhoea (4 studies); and (iv) broader PMR strategies that included malaria treatment (3 studies).

198 The characteristics of included studies are summarised in Table 1. Study findings are presented in
199 Tables 2a and b. As the main outcome indicators are different for interventions with and without RDTs,
200 interventions without RDTs are presented in Table 2a and those with RDTs in Table 2b. The Supporting
201 Information provides detailed characteristics of each study (S3 Table), data collection methods (S4
202 Tables a and b), quality assessment of studies (S5 Table). It also includes heat maps which colour-code
203 the intensity of the intervention and intervention outcomes, in order to explore patterns of results
204 across studies (S6 Tables a and b).

205 Table 1 Summary of study characteristics¹

	Introducing and enhancing ACT use (without diagnostics) n=12 studies	Introducing and enhancing RDT and ACT use n=15 studies	Introducing and enhancing iCCM n=4 studies	Broader private sector strategies including ACT n=3 studies	Total n=34 studies
Study design:					
Cluster randomised control trial	2	7	1	1	11
Individually randomised control trial	2	5	-	-	7
Pre and post without control	5	-	-	-	5
Pre and post with control	3	2	2	-	7
Interrupted time series with control	-	-	1	-	1
Post-intervention with control	-	1	-	2	3
Country²:					
Angola	1	-	-	-	1
Ghana	3	2	-	-	5
Kenya	3	5	-	-	8
Madagascar	2	-	-	-	2
Niger	1	-	-	-	1
Nigeria	3	4	-	-	7
Tanzania	5	1	-	2	8
Uganda	6	3	4	1	14
PMR type:					
Drug shop	4	11	4	2	21
Pharmacy	1	2	-	-	3
Drug shops and pharmacies	-	2	-	-	2
Any PMR	7	-	-	-	7
CHWs as retailers	-	-	-	1	1
Location:					
Rural	5	9	3	1	18
Urban (inc. peri-urban)	-	2	-	-	2
Rural and Urban (or peri-urban)	7	4	1	2	14

206 ¹ Full details of characteristics of each study are provided in S3 Table

207 ² 3 ACT subsidy studies covered multiple countries

208

Table 2a. Study outcomes - Introducing and enhancing ACT use (without diagnostics), and Broader private sector strategies including ACT - % (95% CI or SD) [SE]

Study Design		Outcomes ¹						
First author, Yr published; Country; Data source	Study Arms	ACT uptake			Antibiotic uptake	Patient adherence to treatment regimen	Medicine quality	Health outcomes
		% febrile patients receiving ACT	% febrile patients receiving an antimalarial that received an ACT	% of antimalarial sales volumes that were ACTs	% of febrile patients that received an antibiotic	% of patients dispensed ACT who complete the full dose as directed	% of antimalarials purchased or sold that meet quality standards	
1. Introducing and enhancing ACT use (without diagnostics)								
1.1 Sub-national ACT subsidy programmes								
Kangwana 2011, 2013 [28, 29] Kenya Household survey; mystery shopper survey (market share only)	Intervention: Subsidised paediatric ACTs	53.7 (12.3)* ²	25.4 (6.9)* ³			67.0 (8.5) ²		
	Control: No subsidy	27.3 (15.2) ²	1.8 (1.3) ^{2, 3}			49.4 (24.8) ²		
Lussiana 2016 [30] Angola Outlet survey	Intervention: Subsidised paediatric ACTs			52.8 ^{~4}				
	Baseline: No subsidy			0.0				
Sabot 2009 [31] Tanzania Exit interview (use); outlet survey (sales volumes)	Intervention: Subsidised ACTs and RRP		70.8~ (<5 years) ⁵ 31.1~ (>5 years)	60.3* ^{Λ36}				
	Intervention: Subsidised ACTs and no RRP		40.8~ (<5 years) 48.1~ (>5 years)					
	Control: No subsidy		6.3 (<5 years) 0~ (>5 years)	Negligible				
Talisuna 2012 [32] Uganda Exit interview	Intervention: Subsidised ACTs	26.2* (23.2-29.2)	74.0			82.8 ^{~10}		
	Control: No subsidy	5.6 (4.0-7.35)	Not stated			Not stated		
1.2 National ACT subsidy programmes								
ACTwatch 2017; IE Team 2012; Tougher 2012 [12, 33] Ghana Outlet survey	Intervention: AMFm			51.8* ⁷ (47.9-55.7)				
	Baseline: No subsidy			6.5 ⁷ (3.1-9.8)				

Study Design		Outcomes ¹						
First author, Yr published; Country; Data source	Study Arms	ACT uptake			Antibiotic uptake	Patient adherence to treatment regimen	Medicine quality	Health outcomes
		% febrile patients receiving ACT	% febrile patients receiving an antimalarial that received an ACT	% of antimalarial sales volumes that were ACTs	% of febrile patients that received an antibiotic	% of patients dispensed ACT who complete the full dose as directed	% of antimalarials purchased or sold that meet quality standards	
Kenya Outlet survey	Intervention: CPM 2014			48.2* ^{7,9}				
	Intervention: AMFm			61.4* ⁷ (53.6-69.2)				
	Baseline: No subsidy			12.1 ⁷ (6.0-18.2)				
Madagascar Outlet survey (sales volumes); household survey (use)	Intervention: CPM 2015			7.0* ^{7,8,9}				
	Intervention: CPM 2013			32.0* ^{7,8,9}				
	Intervention: AMFm	8.4* ¹⁰ (4.9-14.3)	44.5~ ¹⁰ (28.8-61.4)	22.0* ⁷ (12.9-31.0)				
	Baseline: No subsidy	3.4 ¹⁰ (2.0-5.7) ⁰	7.2 ¹⁰ (4.4-11.5)	6.8 ⁷ (3.6-10.1)				
Niger Outlet survey	Intervention: AMFm			18.1* ⁷ (12.6-23.6)				
	Baseline: Subsidy			3.7 (1.2-6.2)				
Nigeria Outlet survey (sales volumes); household survey (use)	Intervention: CPM 2015			35.0* ^{7,8,9}				
	Intervention: CPM 2013			27.0* ^{7,8,9}				
	Intervention: AMFm	11.1* ¹⁰ (9.0-13.6)	30.3~ ¹⁰ (25.0-36.1)	17.8* ⁷ (14.4-21.1)				
	Baseline: No subsidy	4.4 ¹⁰ (3.5-5.6)	13.9 ¹⁰ (11.0-17.4)	2.2 ⁷ (1.2-3.2)				
Tanzania - Mainland Outlet survey (sales volumes); household survey (use)	Intervention: CPM 2014			39.2* ^{7,9}				
	Intervention: AMFm	33.7~ ¹⁰	61.5~ ¹⁰	32.1* ⁷ (24-40.3)				
	Baseline: No subsidy	37.9 ¹⁰	63.1 ¹⁰	2.2 ⁷ (1.1-3.3)				
Tanzania – Zanzibar Outlet survey	Intervention: AMFm			60.7* ^{7,9}				
	Baseline: No subsidy			2.0 ⁷				

Study Design		Outcomes ¹						
First author, Yr published; Country; Data source	Study Arms	ACT uptake			Antibiotic uptake	Patient adherence to treatment regimen	Medicine quality	Health outcomes
		% febrile patients receiving ACT	% febrile patients receiving an antimalarial that received an ACT	% of antimalarial sales volumes that were ACTs	% of febrile patients that received an antibiotic	% of patients dispensed ACT who complete the full dose as directed	% of antimalarials purchased or sold that meet quality standards	
Uganda Outlet survey	Intervention: CPM 2015			47.5 ^{7,8,9}				
	Intervention: CPM 2013			43.0 ^{*7,8,9}				
	Intervention: AMFm	44.2 ^{*10} (37.7-50.8) ⁰	82.6 ^{~10} (79.1-85.6)	38.5 ^{*7} (31.5-45.5)				
	Baseline: No subsidy	20.2 ¹⁰ (15.1-26.5)	40.1 ¹⁰ (31.0-49.9)	5.1 ⁷ (2.5-7.7)				
Fink 2013 [34] Uganda Household survey	Intervention: AMFm	47.5 ^{*10} (45.4-49.5)	65.3 [*] (63.9 - 66.8)					
	Baseline: No subsidies	37.2 ¹⁰ (34.7-39.7)	50.8 (48.9 – 52.8)					
Fiore 2018 [35] Pooled Household survey	Intervention: AMFm/CPM	9 ^{*20}						
	Control: No subsidies	4 ²⁰						
Thomson 2014 [36] Tanzania Outlet survey (sales volumes); household survey (use)	Intervention: AMFm	26.9 ^{*11}	52.7 ^{*11}	34.0 ^{*12}				
	Baseline: No subsidy	18.5 ¹¹	30.6 ¹¹	2.2 ¹²				
1.3 Interventions to enhance user adherence to subsidised ACT								
Bruxvoort 2014 [37] Tanzania Client follow-up survey	Intervention: Text message reminders to PMR staff					68.3 (23.4)		
	Control: no text message reminders					69.8 (20.9)		
Cohen 2018 [38] Uganda Client follow-up survey	Intervention: Social marketing packaging					61.1 [2.6] ¹³		
	Intervention: stickers on manufacturer's package					69.5 [3.0] ^{13, 14}		
	Control: Manufacturer's package					63.8		

Study Design		Outcomes ¹						
First author, Yr published; Country; Data source	Study Arms	ACT uptake			Antibiotic uptake	Patient adherence to treatment regimen	Medicine quality	Health outcomes
		% febrile patients receiving ACT	% febrile patients receiving an antimalarial that received an ACT	% of antimalarial sales volumes that were ACTs	% of febrile patients that received an antibiotic	% of patients dispensed ACT who complete the full dose as directed	% of antimalarials purchased or sold that meet quality standards	
Raifman 2014 [39] Ghana Client follow-up survey	Intervention: Long text message reminder to user					62.3 ¹⁵		
	Intervention: Any text message reminder to user					57.1 ¹⁵		
	Control: No text message					58.0 ¹⁵		
4. Broader private sector strategies including ACT								
Bjorkman 2021 [40] Uganda Household survey (use); mystery shoppers (medicine quality)	Intervention: Villages with CHWs as retailers	32.6 ^{10, 13}					90.6* ¹³	
	Control: Villages without	35.0 ¹⁰					73.7 ^{13, 16}	
Bjorkman 2019 [41] Uganda Household survey	Intervention: Villages with CHWs as retailers	67.2 ^{~10, 13}						13.45 ^{~17}
	Control: Villages without	66. ¹⁰						19.4
Thomson 2018 [42] Tanzania Outlet survey	Intervention: Areas with drug shop accreditation			41.6 ¹⁸				
	Control: Areas without drug shop accreditation			25.1 ¹⁸				
Briggs 2014 [43] Tanzania Exit interviews	Intervention: Areas with drug shop accreditation	24.6 ^{~13, 19}			11.0 ^{~13, 19}			
	Control: Areas without drug shop accreditation	16.6 ^{13, 19}			13.4 ^{13, 19}			

210 * p<0.05 for significance of difference from control or baseline shown in table; *^ p<0.05 for significance of difference from baseline data which is not shown; ~ significance not reported

211 ¹ No studies were identified reporting on outcomes related to referral on the basis of protocol

212 ² Outcome is measured among febrile children 3-59 months using AL.

213 ³ % of mystery shoppers dispensed AL.

214 ⁴ % of volumes sold that were subsidised AL. Comparison is from period without subsidised ACTs (2012) to a period with subsidised ACTs (2013).

215 ⁵ Outcome is not presented for all age groups combined.

216 ⁶ Measured among drug shops.

217 ⁷ Outcome is % of volumes sold that were quality-assured ACTs among all private for-profit outlets, including facilities.

218 ⁸ Approximate reading from figure

219 ⁹ Statistical test is for change is from previous survey, not baseline.
220 ¹⁰ Outcome is measured among children <5
221 ¹¹ Outcome is measured among febrile patients that sought care at a specialised drug seller.
222 ¹² Outcome is % of volumes sold that were quality-assured ACTs among specialised drug sellers.
223 ¹³ Author's calculation
224 ¹⁴ Result are pooled for two versions of the sticker message. The sticker message "Malaria is not gone until..." had a larger effect on adherence.
225 ¹⁵ Results shown for drug shop clients only. For all provider types adherence was 61.5% in the control group, 66.4% for the short text message and 64.1% for the long text message.
226 ¹⁶ % of incumbent drug shops selling ACT that passes quality testing.
227 ¹⁷ Outcome is under 5 mortality per 1,000 years of exposure.
228 ¹⁸ % of sales volumes in drug shops that were AL.
229 ¹⁹ Outcome is measured among drug shop clients
230 ²⁰ Outcome is percent of children 0-59 months with fever that took private sector ACTs
231

Table 2b. Study outcomes - Introducing and enhancing RDT and ACT use, and Introducing and enhancing iCCM - % (95% CI where available)

Study Design		Outcomes								
First author, Yr published; Country; Data source	Study Arms	RDT uptake	ACT uptake	Antimalarial dispensing according to RDT result			Antibiotic uptake			Patient adherence
		% febrile patients at study outlet receiving RDT	% febrile patients receiving ACT	% patients with negative test not receiving antimalarial	% patients with positive test receiving ACT	% patients treated according to test result	% patients with negative RDT receiving antibiotic	% patients with positive RDT receiving antibiotic	% all febrile patients receiving antibiotic	% patients dispensed ACT who complete full dose
2. Introducing and enhancing RDT and ACT use										
2.1 RDTs conducted by PMRs										
Ansah 2015 [44] Ghana	Intervention: Trained providers and free RDTs	100 (provided to all)	47.2 ^{2~}	97	92 ¹	not stated	0.6	0	not stated	95
Provider records; Follow-up survey (adherence only)	Control: Trained providers but no RDTs	(RDTs not available)	83.2 ²							No sig. diff from intervention (% not stated)
Cohen 2015 [45] Uganda	Intervention: Trained providers & subsidized RDTs	17.5 ¹	29.3 ²	56.3	40.9	not stated	35 ¹	31 ¹	not stated	
Household survey; Study staff records (dispensing only)	Control: No intervention	9.9	not stated	not stated	not stated	not stated	not stated	not stated	not stated	
Maloney 2017 [46] Tanzania	Intervention: Trained providers and subsidized RDTs	67* [^] (58–71)	32.4 ²	90.8 ²	84.4 ²	not stated	10.5 ²	15.6 ²	not stated	
Exit interviews	Intervention: Trained providers and unsubsidized RDTs	66* [^] (59–72)	32.2 ²	95.0 ²	67.3 ²	not stated	10.0 ²	5.7 ²	not stated	
	Control: No training or RDTs	3	43.2 ²							
Mbonye 2015 ⁸ [47] Uganda	Intervention: Trained providers and subsidized RDTs	97.7	60.8	98.5 ⁴	99.0 ⁴	98.8 ⁴	46.0 (Hopkins 2017)	23.6 (Hopkins 2017)	34.9* (Hopkins 2017)	
Provider records; Follow-up survey (antibiotics only)	Control: Trained providers but no RDTs		99.7						19.4 (Hopkins 2017)	
Dieci, 2023 [48] Kenya	Intervention: Patient subsidies - 90% RDT subsidy, 80% ACT subsidy	35.3* ⁷	72.0* ⁷	90.2*	90.8*					

Study Design		Outcomes								
First author, Yr published; Country; Data source	Study Arms	RDT uptake	ACT uptake	Antimalarial dispensing according to RDT result			Antibiotic uptake			Patient adherence
		% febrile patients at study outlet receiving RDT	% febrile patients receiving ACT	% patients with negative test not receiving antimalarial	% patients with positive test receiving ACT	% patients treated according to test result	% patients with negative RDT receiving antibiotic	% patients with positive RDT receiving antibiotic	% all febrile patients receiving antibiotic	% patients dispensed ACT who complete full dose
Digital sales data	Intervention: Provider incentives - USD 0.86 for RDT, USD 0.76 for ACT with positive RDT, USD 0.29 for recording	27.7* ⁷	77.6 ⁷	89.3*	85.7*					
	Combined: Patient 60% RDT subsidy, 60% ACT subsidy; Provider incentive USD 0.14 for RDT, USD 0.14 for ACT with positive RDT, USD 0.29 for recording	27.9* ⁷	73.1* ⁷	82.2*	87.4*					
	Control: No intervention	8.1 ⁷	86.7 ⁷	24.2	67.9					
Omale 2021 [49] Nigeria Household survey	Intervention: Social group meetings + provider training	64.1* ³								
	Intervention: Social group meetings	62.9* ³								
	Control: No intervention	37.9 ³								
Onwujekwe 2015 [50] Nigeria Results presented for PMRs only exc. public facilities ³ Exit interviews; Provider records (test results)	Intervention: Trained providers, subsidized RDTs, plus school intervention	8.4~ ²	55.9~ ²	13~ ²	71~ ²	not stated	17~ ²	11~ ²	not stated	
	Intervention: Trained providers and subsidized RDTs	12.3~ ²	48.5~ ²	43~ ²	80~ ²	not stated	17~ ²	15~ ²	not stated	
	Intervention: RDT demonstration and subsidized RDTs	24.8 ²	47.5 ²	45 ²	76 ²	not stated	12 ²	17 ²	not stated	
Soniran 2022 [51] Ghana	Intervention: Trained providers and subsidized RDT	38.1 (NB low n=42)	33.3 (NB low n=42)	83.3 (NB low n=12)	not shown as n<10	not shown as n<10				

Study Design		Outcomes								
First author, Yr published; Country; Data source	Study Arms	RDT uptake	ACT uptake	Antimalarial dispensing according to RDT result			Antibiotic uptake			Patient adherence
		% febrile patients at study outlet receiving RDT	% febrile patients receiving ACT	% patients with negative test not receiving antimalarial	% patients with positive test receiving ACT	% patients treated according to test result	% patients with negative RDT receiving antibiotic	% patients with positive RDT receiving antibiotic	% all febrile patients receiving antibiotic	% patients dispensed ACT who complete full dose
Mystery client survey	Control: No intervention	23.3 (NB low n=30)	53.3 (NB low n=30)	not shown as n<10	not shown as n<10	not shown as n<10				
2.2 RDTs conducted by study staff										
Cohen 2015 ¹⁴ [52] Kenya	Intervention: Any ACT subsidy	20.0	41.5 (92% sub)* 35.1 (88% sub)* 36.8 (80% sub)** ⁴	30 (92% sub)~ 40 (88% sub)~ 45 (80% sub)~ ⁻¹	98 (92% sub)~ 98 (88% sub)~ 98 (80% sub)~ ⁻¹	not stated			13.9 (92% sub) 12.3 (88% sub) 8.5 (80% sub)** ⁴	
	Intervention: Any RDT subsidy	29.1*	40.7 ⁴	not stated	not stated	not stated			-	
	Control: No ACT subsidy	21.4	19.0 ⁴						18.5 ⁴	
	Control: No RDT subsidy	7.6	38.9 ⁴						-	
Ikwoobe 2013 [53] Nigeria	Intervention: Free RDTs	100 (provided to all)	42.0~ ⁷	48.4	85.7	not stated				
	Control: No intervention	(RDTs not available)	70.7 ⁷							
Laktabai 2020 [54] Kenya	Intervention: 50% RDT subsidy and 100% ACT subsidy	98.6* ⁹	15.7~	94.9 ⁴	77.4	92.2 ⁴				
	Intervention: 50% RDT subsidy and 67% ACT subsidy	100* ⁹	23.7~	93.9 ⁴	87.0	92.4 ⁴				
	Intervention: No RDT subsidy and 100% ACT subsidy	96.2	26.8~	93.5 ⁴	92.2	93.2 ⁴				
	Intervention: No RDT subsidy and 67% ACT subsidy	96.5	27.2	91.0 ⁴	84.8	89.5 ⁴				
Modrek 2014 [55] Nigeria	Intervention: Text messages to adult patients, free RDT and ACT	100 (provided to all)		76.9* ⁵		79.8* ⁵				

Study Design		Outcomes								
First author, Yr published; Country; Data source	Study Arms	RDT uptake	ACT uptake	Antimalarial dispensing according to RDT result			Antibiotic uptake			Patient adherence
		% febrile patients at study outlet receiving RDT	% febrile patients receiving ACT	% patients with negative test not receiving antimalarial	% patients with positive test receiving ACT	% patients treated according to test result	% patients with negative RDT receiving antibiotic	% patients with positive RDT receiving antibiotic	% all febrile patients receiving antibiotic	% patients dispensed ACT who complete full dose
Follow-up survey	Control: Free RDT and ACT	100 (provided to all)		58.5 ⁵		65.5 ⁵				
Saran 2016 [56] Uganda	Intervention: Free RDT and ACT subsidy									No sig. diff from control (% not stated)
Patient follow-up survey	Intervention: ACT subsidy									66.5
2.3 RDTs conducted by CHWs, with medicines provided by PMRs										
O'Meara 2016 [57] Kenya	Intervention: Free RDT and 50% ACT subsidy	71.1~	43.9~	72.5 ⁴	81.8* ¹⁰	76.2 ⁴				
CHW records (RDT); follow-up survey (medicines dispensed)	Intervention: Free RDT and no ACT subsidy	67.0~	33.0~	80.0 ⁴	71.4	77.6 ⁴				
	Intervention: No RDT subsidy and 50% ACT subsidy	42.5~	32.7~	87.1* ^{4,9}	84.0* ¹⁰	85.7* ⁴				
	Intervention: No RDT subsidy and no ACT subsidy	42.0	29.0	92.6* ^{4,9}	58.3	76.5 ⁴				
O'Meara 2018 [58] Kenya	Intervention: Free RDT and ACT subsidy	55.0* ³		70.1 ⁴	90.0	88.5* ⁴	47.3	25.2	22.6	
Household survey ¹⁵	Control: No intervention	44.7 ³		54.4 ⁴	83.8	80.7 ⁴	69.3	30.2	26.0	
3. Introducing and enhancing iCCM										
Awor 2014 [59] Uganda	Intervention: iCCM	87.7* (79.0–96.4)	80.7*	91.0 (NB low n=11)	100 (NB low n=33)	97.6	not stated	not stated	60* ¹¹	

Study Design		Outcomes								
First author, Yr published; Country; Data source	Study Arms	RDT uptake	ACT uptake	Antimalarial dispensing according to RDT result			Antibiotic uptake			Patient adherence
		% febrile patients at study outlet receiving RDT	% febrile patients receiving ACT	% patients with negative test not receiving antimalarial	% patients with positive test receiving ACT	% patients treated according to test result	% patients with negative RDT receiving antibiotic	% patients with positive RDT receiving antibiotic	% all febrile patients receiving antibiotic	% patients dispensed ACT who complete full dose
Exit interviews (RDT uptake, medicines dispensed); Observation (dispensing by test result)	Control: No intervention	0	41.1				not stated	not stated	73.5 ¹¹	
Bagonza 2021 [60] Uganda	Intervention: iCCM with peer supervision					53.5-66.3 ¹²				
Provider records	Control: Standard iCCM					47.1-67.1 ¹²				
Kitutu 2017 [61] Uganda	Intervention: iCCM	47.8*	22.4	not stated	not stated	not stated ¹³	not stated	not stated	not stated	
Exit interviews	Control: No intervention	0.39	14.3				not stated	not stated	not stated	
Mbonye 2020 [62] Uganda	Intervention: iCCM	86.9*	33.1* ⁶	87.4	94.3* ⁶	not stated	not stated	not stated	not stated	
Provider records	Control: No intervention	58.5	38.7 ⁶	95.6	83.0 ⁶	not stated	not stated	not stated	not stated	

* p<0.05 for significance of difference from control or baseline shown in table; *^ p<0.05 for significance of difference from baseline data which is not shown; ~ significance not reported

No studies were identified reporting on outcomes related to medicine quality or health outcomes. Only one study (Ansah et al) reported Referral according to protocol

¹ approximate reading from figure

² Not stated in original papers; taken from Visser et al review, based on Visser et al's contact with original study authors

³ For Omale 2021 the indicator reported is "% febrile patients receiving RDT from any provider"; for O'Meara 2018 the indicator reported is "% febrile patients receiving any malaria test from any provider"

⁴ For Laktabai 2020, O'Meara 2016 and O'Meara 2018 the indicator reported is "% patients with negative RDT not receiving ACT"; For Cohen 2015 (Kenya) and O'Meara 2018 results are reported from any provider. For Mbonye 2015 the indicator reported is "% patients with negative RDT not receiving AL or rectal artesunate" and "% patients with positive test receiving AL or rectal artesunate"

⁵ For Modrek 2014 the indicators reported are based on medicines taken by patients (not on those dispensed); the indicator "% patients with negative test not receiving antimalarial" is reported only for the 57% of patients who bought both an antimalarial and drugs to treat their symptoms

⁶ For Mbonye 2020 the indicators reported are "% all patients receiving AL" and "% patients with positive test receiving AL"

⁷ For Ikwoobe 2013 the indicator reported is "% patients seeking to purchase antimalarials receiving ACT" rather than of all febrile patients. For Dieci 2023 the denominator for these indicators is "all people who bought an antimalarial or an RDT"

⁸ Also related studies by Hutchinson et al 2017 (including follow up survey findings), Hansen et al 2017

⁹ Significance of difference between the subsidised RDT groups and the unsubsidised RDT groups, averaged across the price levels of ACTs

247 ¹⁰Significance of difference between the subsidised ACT groups and the unsubsidised ACT groups, irrespective of whether they received an RDT subsidy
248 ¹¹ For Awor 2014 the indicator is reported out of all sick children, not just those with fever (though 98% of children reported fever)
249 ¹² Bagonza 2021 used interrupted time series – table includes range of results across 7 monthly post-intervention data points (no statistical difference in trend between intervention and control)
250 ¹³ Kitutu 2017 do not report this indicator but do report an alternative indicator of appropriate treatment for malaria (see text)
251 ¹⁴ Cohen 2015 Kenya results for the 11 treatment arms are not presented separately. Rather the effect of ACT and RDT subsidies is estimated by pooling arms in different combinations
252 ¹⁵ Antibiotic uptake results for this study are available in both O’Meara 2018 and Laktabai 2022; we present the results from O’Meara 2018 as they relate to the final point of evaluation. The direction and size of
253 effects reported are similar in the two papers.
254
255

256 We present the results by each of the four intervention categories.

257 **Introducing and enhancing ACT use (without diagnostics)**

258 The 12 studies on introducing or enhancing ACT use all included retail sector ACT subsidies. The findings are presented
259 in 3 groups: evaluations of sub-national ACT subsidies (4 studies), national ACT subsidies (5 studies, of which 3 are
260 multi-country), and interventions to improve adherence to subsidised ACT (3 studies) (Table 2a).

261 **Sub-national ACT subsidy programmes**

262 Four evaluations were of sub-national ACT subsidies in Kenya, Uganda, Tanzania and Angola [28, 30-32]. All the
263 projects started pre-AMFm, lasting 8 months to 3 years. The interventions were similar, involving an ACT subsidy
264 combined with branding of the subsidised product, behaviour change communications, PMR training (one day where
265 duration stated), and recommended retail prices (RRP). Kangwana et al (Kenya) and Lussiana et al (Angola) involved
266 subsidies of paediatric ACT only [28, 30], while Sabot et al (Tanzania) and Talisuna et al (Uganda) subsidised ACTs for
267 all age groups [31, 32]. In 3 studies, the subsidised ACTs were delivered directly to participating PMR, while in Sabot
268 et al they were provided through a designated wholesaler. The studies covered a range of low, moderate and high
269 malaria transmission settings, with three in rural areas, and one covering urban and rural areas. The number of
270 participating PMRs ranged from 151 to 225 (not reported in one study). In all studies eligible PMR included drug shops
271 and/or pharmacies, while Kangwana et al also included general shops. Three studies were pre-post evaluations: of
272 these, two included a control group [31, 32], and one did not [30]. The fourth study was a cluster randomized control
273 trial [28].

274 There were large increases in ACT uptake across all studies with, for example, a 26.4 percentage point difference in
275 febrile patients receiving ACT between the intervention and control arms in Kenya (household survey) [28], and a 20.6
276 percentage point difference in Uganda (exit interviews) [32]. In Tanzania the market share of ACT among PMR
277 antimalarial sales was negligible in control areas and over 60% at endline (outlet survey) [31]. Where measured, these
278 effects were observed across all socio-economic groups, with ACT uptake higher in intervention areas among all
279 quintiles in Kenya [28], and even improving more among households with less education in Uganda [32]. Changes in

280 other outcomes relevant to this review were generally not measured, with the exception of patient adherence to ACT
281 dosing in Kenya, where the difference was not statistically significant (household survey) [28].

282 It was not possible to attribute variations in intervention effectiveness across studies to specific intervention
283 components, due to the small number of studies, similarity of programmes, and differences in data collection methods
284 (S6 Table a). The Tanzanian study implemented an RRP in one of the two intervention areas with mixed results: uptake
285 was higher in the RRP area for children but not for adults, reflecting the finding that for adult doses the RRP appeared
286 to have had the unintended effect of artificially inflating prices above the market rate [31].

287 **National ACT subsidy programmes**

288 Five studies explored the impact of national ACT subsidy programmes – the AMFm and its successor the Co-Payment
289 Mechanism (CPM). The AMFm covered 7 African countries: Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, and
290 Tanzania (mainland and Zanzibar) from 2010-2012 [12]. It involved price negotiations with manufacturers, and subsidy
291 of quality-assured ACTs at the “factory-gate”. Subsidised ACTs were imported by registered first-line buyers, and then
292 distributed to PMRs through their usual distribution chains. Supporting interventions at country level involved some
293 combination of behaviour change communications, provider training, and RRP, with considerable variation in their
294 duration and scale across countries. Following a transition period in 2013, the CPM replaced AMFm in 6 countries
295 (Ghana, Kenya, Madagascar, Nigeria, Tanzania, Uganda), involving similar intervention components to AMFm, but with
296 differences in the source of funds, process of approving orders, and lower subsidy levels [8].

297 Three studies assessed the impact of AMFm only, including the multi-country AMFm Independent Evaluation [12, 33],
298 and two single country studies by Fink et al in Uganda and Thomson et al in Tanzania [34, 36]. Two later multi-country
299 studies covered both the AMFm and CPM periods [8, 35]. The studies covered a range of low, moderate and high
300 malaria transmission settings. Four of the studies were pre-post comparisons without control, while Fiore et al
301 conducted a pre-post evaluation comparing countries with and without AMFm/CPM [35].

302 The studies found increases in the market share of quality-assured ACTs in private for-profit outlets across all countries
303 implementing these subsidy programmes (outlet surveys). In the five countries with data from the CPM period (Kenya,
304 Madagascar, Nigeria, Tanzania, Uganda) increased market share under AMFm was either sustained or rose further,
305 except in Madagascar, where it increased substantially in the initial CPM period, but then fell to pre-AMFm levels [8].

306 The magnitudes of market share increases from pre-AMFm to the most recent data point were over 30 percentage
307 points everywhere but Madagascar and Niger.

308 Data on the impact on ACT use from household surveys are somewhat more limited, and may also reflect concurrent
309 changes in public sector ACT provision. Pre-post data from Madagascar, Nigeria and Uganda show increases in ACT
310 use among febrile children under 5, reflecting substantial substitution away from other antimalarials [33]. In Tanzania,
311 national data show a decrease in the percent of febrile patients receiving ACT overall following AMFm introduction
312 [33], but more detailed sub-national data indicate that this partially reflected reduced use of ACTs in public facilities
313 associated with an increase in diagnostic testing, while ACT use among patients visiting PMR increased [36]. Fiore et
314 al compared changes over time in ACT use among febrile patients that sought care in the private sector in AMFm/CPM
315 countries (Ghana, Nigeria, Uganda) and 12 comparator countries [35]. They found that AMFm/CPM increased use
316 overall, but this seems to be mostly driven by improvements in Uganda. No other outcomes relevant to this review
317 were reported by these studies.

318 As with the sub-national pilots, there was no evidence that increases in ACT uptake were limited to certain socio-
319 economic groups. Increases in market share and use were similar in urban and rural areas [12, 35]; and where overall
320 ACT use was shown to have increased (Madagascar, Nigeria, Uganda), this was also documented among children in
321 the poorest two quintiles [33, 34]. However, in Nigeria the largest increases in market share were recorded among the
322 top two quintiles [33].

323 It is challenging to identify the contribution of specific intervention components to performance (S6 Table a). For
324 example, Kenya and Tanzania had sustained implementation of communications activities and adherence to RRP
325 seemed strong, and both countries saw large, sustained market share increases. However, large increases were also
326 seen in Uganda, despite poor adherence to RRP, and very limited behaviour change communications. The
327 Independent Evaluation attributed smaller market share increases in Madagascar and Niger during AMFm to low
328 ordering, political and economic disturbances, and the high proportion of general retailers among PMRs who may have
329 been viewed as less appropriate ACT sellers than pharmacies/drug shops [33]. However, much higher market share
330 was achieved in Madagascar under the CPM in 2013 [8], indicating that their retail market composition was not
331 necessarily a barrier to higher ACT uptake.

332 **Interventions to enhance user adherence to subsidised ACT**

333 Three RCTs evaluated interventions to improve adherence to the ACT dosing regimen (% patients dispensed ACT who
334 complete the full dose as directed). In Tanzania, Bruxvoort et al sent regular text messages to PMR staff to remind
335 them about the correct dispensing advice to give patients [37]. In Ghana, Raifman et al sent text messages to patients
336 for 3 days after their visit to a facility or PMR to remind them to complete the full course, with patients randomly
337 allocated to receive either a long or short message [39]. In Uganda, Cohen et al modified the ACT packaging to provide
338 further information on adherence either through additional social marketing packaging or a simpler sticker attached
339 to existing packaging [38]. These were all short, focused interventions (2.5-5 months) involving 9-84 providers, in
340 moderate to high transmission settings, and in a mix of urban and rural, or rural only areas. Adherence was measured
341 at follow-up visits to patient in their homes.

342 Improvements in adherence either did not occur or were modest (less than 6 percentage points difference between
343 intervention and control) across the three studies. In Uganda, the simpler sticker was found to be more effective than
344 more complex social marketing packaging [38]. In Ghana, results from drug shops only showed no significant effect for
345 either text message, though results for all provider types combined (drugs shops and facilities) indicated that the
346 shorter text message improved adherence while the longer message did not [39].

347 **Introducing and enhancing RDT and ACT use**

348 15 studies were identified on introducing or enhancing RDT use in PMRs, all but one [51] of which either also included
349 ACT subsidies or were conducted in the context of a national ACT subsidy programme. We present the studies in two
350 groups: the first group covers 13 studies where RDTs were conducted at the PMR, while the second group covers 2
351 studies where community health workers (CHWs) conducted RDTs and provided vouchers for ACT purchase at PMRs
352 in the same area [57, 58] (Table 2b).

353 **RDTs conducted at PMRs**

354 Of the 13 studies where RDTs were conducted at PMRs, most involved drug shops with some including pharmacies.
355 Reflecting very low routine RDT provision by PMRs in most settings, nine studies involved introduction of RDTs to
356 PMRs where they were not previously used, while only 4 explored interventions to strengthen existing RDT use by

357 PMRs [45, 48, 49, 51]. The intervention package also involved ACT subsidies in 6 studies [47, 48, 52, 54-56], while in 5
358 of the remaining 7, AMFm or CPM subsidised ACTs were available in the market [44-46, 50, 53]. Eight studies tested
359 an intervention package with PMR staff conducting the RDTs [44-51]; while in 5 studies the RDTs were conducted by
360 research team members stationed at the PMR [52-56]. Of the latter group 3 studies generally had relatively short
361 durations of 4 months or less (S5 Table).

362 For the 8 studies where PMR staff conducted the RDTs, the interventions involved PMR training (1-4 days) and
363 supervision (weekly, monthly or quarterly). In addition, Dieci et al tested the provision of performance incentives to
364 pharmacy staff for providing RDTs, providing ACT conditional on a positive test, and appropriate record keeping [48].
365 Five studies included communications activities: Ansah et al, Mbonye et al and Soniran et al conducted community
366 meetings [44, 47, 51]; Omale et al tested sensitisation and education of women's and men's social groups [49]; and
367 Onwujekwe et al included a school intervention [50]. In 5 studies RDTs were provided directly to PMRs by the study
368 team [44, 47, 48, 50, 51], in 2 studies PMRs purchased RDTs through designated wholesalers [45, 46], and in one study
369 RDTs were obtained through regular distribution channels [49]. In one study RDTs were provided free to users [44]; in
370 most others RDTs were subsidised, except for Omale et al and one intervention arm in Maloney et al and Dieci et al
371 where no subsidy was provided [46, 48, 49]. The number of providers included varied from 7 [44] to 262 [46], and the
372 duration in months from 3 [49] to 17 [44]. All the studies were conducted in rural areas, while 3 also included urban
373 areas, and all in situations of moderate or high malaria transmission, except Dieci et al (mainly low transmission) [48].
374 All studies were cluster randomised trials, with the exception of Maloney et al and Soniran et al, which were pre-post
375 evaluations comparing intervention and control districts [46, 51].

376 The five studies where RDTs were conducted by research team members were not aiming to evaluate a comprehensive
377 RDT intervention package, but rather to test specific hypotheses about user behaviour in a small number of PMRs
378 (ranging from 1-10 retailers). Laktabai et al and Cohen et al studied the impact of varying the level of RDT and ACT
379 subsidy, with for Laktabai et al the ACT subsidy being conditional on a positive RDT result [52, 54]. The other 3 studies
380 in this group provided RDTs for free: Saran et al investigated whether having an RDT increased patient adherence to
381 the full treatment dose; Modrek et al investigated the effect of text message reminders on whether patients later
382 consumed the correct medicine for their RDT result; and Ikwuobe et al simply assessed medicines dispensed when an
383 RDT was conducted [53, 55, 56]. Three of these five studies were in rural and two in urban areas, and all under

384 moderate or high malaria transmission. Four studies individually randomised the intervention at the patient level,
385 while Ikwuobe et al compared one intervention and one control PMR [53].

386 **RDT uptake**

387 RDT uptake refers to the percent of febrile patients at the outlet receiving an RDT. In 11 of the studies RDT uptake was
388 zero or minimal in the absence of any intervention, but in 4 studies RDTs were already used, ranging from 8% of
389 pharmacy clients in Kenya (digital sales records) [48], to 10% of drug shops in Uganda (household survey) [45], 23% of
390 drug shops in Ghana (mystery shoppers) [51], and 38% of all providers in Nigeria (household survey - data not
391 presented for PMR clients only) [49].

392 In two of the studies where PMRs conducted RDTs by Ansah et al and Mbonye et al, RDT uptake following the
393 intervention was reported to be at or close to 100%, though both relied on the PMRs' own records, raising the risk
394 that staff will be more likely to record patients who were tested, or of other Hawthorne effects [44, 47]. For the 6
395 other studies where PMRs conducted RDTs, uptake in the intervention group was close to two thirds for Maloney et
396 al (exit interviews) [46] and Omale et al (household survey) [49], close to one third for Dieci et al (digital sales data)
397 [48] and Soniran et al (mystery shoppers) [51], but under 20% for Onwujekwe et al (exit interviews) [50] and Cohen et
398 al Uganda (household survey) [45]. Two of the studies where research staff conducted RDTs reported on uptake based
399 on study team records, with results over 96% in Laktabai et al, but under 30% in Cohen et al [52, 54] (in Modrek et al,
400 Saran et al and Ikwuobe et al study staff provided RDTs to all intervention patients so uptake is not presented).

401 **Dispensing according to test result**

402 Our standard definition of correct dispensing by RDT result was a patient with a negative test receiving no antimalarial,
403 and one with a positive test receiving an ACT, although there was variation in these indicators across studies. For
404 example, some studies defined correct dispensing for negatives as not receiving ACT rather than not receiving any
405 antimalarial. Of the 9 studies reporting rates of correct dispensing for positive RDTs, Ansah et al and Mbonye et al had
406 very high rates of 92% and 99% respectively based on provider records [44, 47]. Rates over 80% were also seen in at
407 least one arm in 3 studies based on exit interviews [46, 50, 54], two studies based on study staff records [52, 53], and
408 one based on digital sales data [48], but Cohen et al reported a much lower rate of 41% based on household survey
409 data [45].

410 Of the 11 studies reporting rates of correct dispensing for negative RDTs, 5 reported rates over 90% in at least one
411 arm including the two studies based on provider records [44, 47], two based on exit interviews [46, 54], one based on
412 study staff records [52], and one based on digital sales data [48]. However, the other studies encompassed a wide
413 range from 83% (mystery shoppers – though sample size very low) [51], to 77% (patient follow up survey) [55], 56%
414 (household survey) [45], 48% (study staff records) [53] and 13-43% (exit interviews) [50]. Whether RDTs were
415 performed by PMR or study staff did not appear to have a systematic effect on rates of correct dispensing for positive
416 or negative RDTs (S6 Table b).

417 Ansah et al and Mbonye et al also assessed dispensing in relation to microscopy results based on samples collected at
418 the same time as the RDT test but examined at a later date in research team laboratories [44, 47]. As these data can
419 be presented for all patients regardless of whether they received an RDT, they can be used to assess targeting of
420 medicines in the intervention and control/baseline in relation to true parasitological status. Both studies reported
421 substantially higher rates in the intervention than control arm of correct dispensing by microscopy results (slide
422 positive receives ACT and slide negative does not receive antimalarial), with significant differences of 47 percentage
423 points [44] and 39 percentage points [47] (data not presented in Tables). In the intervention arms rates of correct
424 dispensing by microscopy result were lower than when based on RDT result, despite extremely high RDT uptake in
425 these two studies. This reflected low specificity of RDTs compared to microscopy of 63% [47] and 70% [44] i.e. RDTs
426 led to a high number of false positives. While this could partially reflect the detection of HRP2 antigen persistence by
427 RDTs, Ansah et al note that specificity was particularly low in three drug shops, raising the possibility that some PMRs
428 were incorrectly reporting positive RDT results to justify antimalarial sales [44].

429 **ACT uptake**

430 A comparison of ACT uptake (% all febrile patients receiving ACT) with and without RDT introduction was reported in
431 5 studies. While ACT uptake is not an indicator of quality of care as the latter depends on whether the patients are
432 parasitaemic, ACT uptake is a useful indicator of potential savings in ACT from RDT introduction. Five studies showed
433 substantially lower ACT uptake in the intervention arm compare to the control: Ansah et al of 83% v. 47% (provider
434 records), Mbonye et al of 99.7 v. 61% (provider records), Ikwuobe et al of 71 v. 42% (study team records), Dieci et al
435 of 87% v. 72-78% (digital sales data), and Soniran of 53% v. 33% (mystery shoppers) [44, 47, 48, 51, 53]. It was notable
436 that Ansah et al, Mbonye et al and Dieci et al reported very high rates of ACT uptake in control arms without RDTs

(>83%). Maloney et al (exit interviews) and Cohen et al (household survey) showed no significant difference in ACT uptake between arms, but the levels in their intervention arms (32% and 35-41% respectively) [46, 52] were lower than in the intervention arms of the five studies showing large reductions.

Other outcomes

Antibiotic uptake was reported in six studies post-intervention, for RDT negatives ranging from 0.6% (provider records) [44] to 46% (provider records) (Mbonye et al, reported in Hopkins 2017 [63]), and for RDT positives from zero (provider records) [44] to 31% (household survey) [45]. Only Mbonye et al reported on the difference in antibiotic uptake with and without RDT introduction, which they found to be 15.5 percentage points higher in the intervention arm (Mbonye et al, reported in Hopkins 2017 [63]). Two studies assessed the impact of RDT provision on patient adherence (% patients dispensed ACT who completed the full dose) but neither found a significant impact (patient follow-up surveys) [44, 56]. Only one study reported the proportion of patients where a referral was required who were referred; by protocol Ansah et al required that all RDT negatives were referred to health facilities, and they found that this occurred in 80% of cases, of which 62% later reported that they went to the referral facility (patient follow-up survey – not presented in Tables) [44]. Other studies reported overall referral levels but these are hard to interpret without knowing whether referral was required. No studies reported on other review outcomes, or on variations in effectiveness by socio-economic status or urban/ rural location.

Impact of variation in RDT intervention design

The impact of variation in intervention design can be assessed either within studies with multiple intervention arms, or by comparing across studies with different intervention packages (Table 2b and S6 Table b). When comparing across studies, there is some indication that lower RDT retail prices were associated with higher RDT uptake. The three studies with very high RDT uptake provided RDTs free [44] or had relatively low RRP or actual prices of USD 0.21 [54] and USD 0.23 [47], compared with USD 0.5 [45] and USD 0.69 [50] in two of the studies with low uptake (all prices converted to 2020 USD). By contrast, Cohen et al reported low uptake at a price of only USD 0.23 [52], but given that this was the earliest study identified (2009) low uptake could partially have reflected patients' unfamiliarity with RDTs. Three studies assessed the impact of varying the RDT price as part of their study design. Maloney et al found no difference in RDT uptake (exit interviews) between a subsidised RRP of USD 0.36 and unsubsidised of USD 0.75 [46].

463 Cohen et al found no substantive difference in RDT uptake when comparing free RDTs with those subsidised at USD
464 0.23, but a significant increase in RDT uptake from 7.6 to 29.1% (study staff records) when comparing any subsidy (free
465 or USD 0.23) with those unsubsidised at USD 1.51 [52]. In Laktabai et al a subsidised price of USD 0.21 compared with
466 an unsubsidised price of USD 0.41 had limited impact as RDT uptake was over 96% in all arms (study staff records)
467 [54]. These varying results likely reflect the considerable variation in the level of the unsubsidised price across studies.

468 Two of these studies also explored variation in the ACT subsidy level. Laktabai et al found that varying whether ACT
469 was provided free or subsidised (conditional on a positive RDT) had no impact on RDT uptake or antimalarial
470 dispensing, reflecting very high compliance with guidelines in all study arms (study staff records) [54]. Cohen et al
471 found varying the ACT subsidy from 80 to 92% had no impact on ACT uptake overall, although it substantially increased
472 compared to the unsubsidised price of USD 7.48 [52]. Varying the ACT subsidy from 80 to 92% had no impact on
473 dispensing according to a positive RDT (which was high for all groups), but the lower ACT subsidy increased correct
474 dispensing for RDT negative patients (no antimalarial) (study staff records).

475 Of the 6 studies where PMRs conducted the RDT there was some indication that interventions with higher training
476 and supervision intensity had better dispensing outcomes [44, 47] (S6 Table b), but this could also have reflected
477 outcome measurement based on provider records. Notably Maloney et al also reported high rates of appropriate
478 dispensing (exit interviews) but had shorter training and less frequent supervision [46]. There was no clear pattern in
479 RDT uptake across studies based on whether RDTs were directly delivered to PMRs by the study team (S6 Table b).

480 Four studies explored variations in other supportive measures across study arms, with two testing the impact of adding
481 provider training [49, 50], and one each the addition of social group mobilisation [49], a school intervention [50], text
482 message reminders to users [55], and provider performance incentives [48]. Omale et al found that the arm receiving
483 social group mobilisation had higher RDT uptake (household survey) [49], and Modrek et al found that the arm where
484 patients received text messages reminding those RDT positive to take ACT and those RDT negative not to take any
485 antimalarials were significantly more likely to consume antimalarials in line with their RDT result (patient follow-up
486 survey) [55]. However, Onwujekwe et al found no evidence that adding provider training or a school intervention
487 improved RDT uptake or dispensing (exit interviews) [50], and Omale et al found no difference in RDT uptake from
488 adding provider training to social group mobilisation (household survey) [49]. Dieci et al found no significant
489 differences between 3 intervention arms comparing (i) patient subsidies for RDTs and ACTs (condition on a positive

test), (ii) provider performance incentives for appropriate RDT use, ACT provision and record keeping, and (iii) a combined arm with both patient subsidies and provider incentives (digital sales data) [48].

RDTs conducted by CHWs, with medicines provided by PMRs

Two studies by O'Meara et al, both in Western Kenya, used a different intervention model, where CHWs located close to PMRs were trained to conduct RDTs and provided vouchers for ACT purchase at PMRs for those patients with a positive RDT result [57, 58]. Both studies were conducted in rural areas, with low or low to moderate malaria transmission. The earlier study was a 12-month individually randomised trial with a factorial design involving 11 PMRs [57]. Individuals with a malaria-like illness who had not yet sought treatment were recruited from their homes and allocated to receive an unsubsidised or fully subsidised RDT by a CHW and one of two levels of ACT subsidy. The later study was a 20-month cluster randomised trial involving 42 PMRs, comparing community clusters with CHWs providing free RDTs and conditional ACT subsidies with clusters where CHWs did not provide RDTs [58]. In both studies ACTs were supplied to PMRs through the standard supply chain. No training or supervision on malaria case management was provided to PMRs beyond a brief orientation on the vouchers and ACT dosing, but the later study included community level communications activities [58].

O'Meara et al 2016 found that patients offered a free RDT had higher RDT uptake at CHWs, and higher malaria test uptake overall (RDT or microscopy), with an adjusted difference of 18.6 percentage points (patient follow-up survey) [57]. Receiving the conditional ACT subsidy did not lead to higher test uptake, but did increase dispensing in line with a positive RDT result by 19.5 percentage points (patient follow-up survey) [57]. Appropriate ACT use following a test was highest when clients paid for their RDT and were given a conditional voucher for their ACT. However, as RDT uptake was low when they were unsubsidised, overall targeting of ACTs in all participants was highest in the groups that received a free RDT. This analysis informed the design of the intervention for the cluster randomised trial, which included a free RDT and conditional ACT subsidy [58]. Household survey data showed that at the community level this intervention led to significantly better results in the intervention arm compared to the control arm for test uptake (55% v 45%), and correct dispensing for those with a negative RDT (70% v 55%), and with a positive RDT (90% v 84%) [58]. The provision of antibiotics was slightly lower in the intervention arm (47% v 69% for RDT negatives; 25% v 30% for RDT positives) (significance not reported).

516 Introducing and enhancing iCCM

517 Four studies were identified on introducing and enhancing iCCM in PMRs, all from Uganda (Table 2b). The iCCM
518 interventions studied covered the treatment of children under 5 years for malaria (using RDT and ACT), pneumonia
519 and diarrhoea. Three studies evaluated the introduction of iCCM [59, 61, 62], and a fourth the addition of peer
520 supervision to an existing iCCM programme [60]. All four studies included drug shops in rural areas, with one also
521 including private clinics and urban areas [62]. All studies were in areas of moderate or high malaria transmission, with
522 the exception of Kitutu et al, where transmission was low to moderate [61].

523 The three studies of iCCM introduction included one cluster randomised trial [62] and 2 pre-post evaluations with
524 control [59, 61], with the interventions involving PMR training (4-5 days), supervision (weekly to start, or monthly),
525 and communications activities (eg radio, public meetings, shop branding, posters, leaflets, and/or training CHWs or
526 Village Health Teams). Supplies, including ACTs and RDTs, respiratory timers, and medicines for pneumonia and
527 diarrhoea were distributed directly to PMRs [59, 62] or through a designated wholesaler [61]. RDTs were provided free
528 to users and ACTs were subsidised [59, 61]. The number of intervention providers ranged from 44 [59] to 61 [61], and
529 the intervention duration from 9 [59] to 26 months [62].

530 The three studies introducing iCCM to PMRs all showed substantial increases in RDT uptake. Awor et al and Kitutu et
531 al had zero or negligible uptake in the control arm compared to uptake in the intervention arm of 88% and 48%
532 respectively (both exit interviews) [59, 61]. In Mbonye et al uptake was 59% in the control arm compared to 87% in
533 the intervention arm (provider records) [62]. Awor et al and Mbonye et al both reported very high rates of dispensing
534 on the basis of RDT result of 100% and 94% respectively for positive RDTs, and 91% and 87% for negative RDTs, though
535 these figures are based on direct observation [59] and provider records [62]. Kitutu et al did not report these indicators
536 but did find a substantial difference in a composite “appropriate treatment” indicator based on testing and dispensing
537 by protocol for both febrile and afebrile children between the intervention (57%) and control (1%) areas (exit
538 interviews) [61]. The three studies report mixed findings on ACT uptake: Awor et al show substantially higher uptake
539 in the intervention arm (exit interviews) [59], Mbonye et al show significantly lower uptake (provider records) [62],
540 and Kitutu et al no difference (exit interviews) [61]. The effect on antibiotic use is reported by Awor et al only, showing
541 a significantly lower uptake by 13 percentage points (exit interviews) [59].

542 The fourth iCCM study by Bagonza et al was an interrupted time series evaluation of the use of peer supervision to
543 strengthen iCCM in 60 rural drug shops [60]. Selected PMR staff received a 3-day refresher training, and then made
544 monthly visits to their peers for 8 months [60], while all products were provided by standard supply chains. The peer
545 supervision had no impact on dispensing by test result (provider records) (the effect on other outcomes is not
546 reported).

547 No iCCM studies reported other review outcomes or on variation in effectiveness by socio-economic status or urban /
548 rural location.

549 Broader private sector strategies including ACT

550 Three studies were identified evaluating broader PMR interventions that included ACT provision. As none included
551 RDTs, the results are presented in Table 2a which shows studies involving ACT subsidies to facilitate comparison across
552 similar outcomes. Two studies evaluated the Accredited Drug Dispensing Outlet (ADDO) programme in Tanzania [42,
553 43], which had been implemented in rural and urban areas of 14 of Tanzania's 21 region at the time of the studies,
554 covering around 3,800 PMRs. The ADDO programme involved an initial PMR training of 35 days and regular
555 supervision. ADDOs were permitted to stock 49 prescription-only medicines, including ACT, which was subsidised
556 through AMFm at the time of the studies. Both studies were post-intervention assessments comparing ADDO with
557 non-ADDO regions. Briggs et al covered one ADDO and one non-ADDO region, with moderate and low to moderate
558 malaria transmission [43], while Thomson et al was nationally representative covering areas with low, low to
559 moderate, and moderate transmission [42]. The studies found weak evidence that the ADDO programme improved
560 ACT uptake: Thomson et al found market share to be 42% in ADDO and 25% in non-ADDO regions based on outlet
561 survey data though the difference was of borderline significance [42]. Briggs et al reported the proportion of febrile
562 patients obtaining ACT to be 25% in the ADDO region compared with 17% in the non-ADDO region (exit interviews)
563 [43].

564 The third study was a randomised controlled trial evaluating the establishment of the Living Goods model where,
565 following a 2-week training, a cadre of CHWs were established as retailers in over 800 rural Ugandan villages with high
566 malaria transmission, selling a package of health-related commodities including ACTs but not RDTs [41]. There was no
567 evidence that the intervention improved ACT uptake (household survey) [40, 41]. However, it was found to have a

568 “spillover effect” of improving the quality of ACTs sold to mystery shoppers by incumbent drug shops in the villages
569 where the CHW retailers were located, with 91% of ACTs meeting quality standards in intervention villages, compared
570 with 74% in the control [40]. In addition, the programme was found to improve under 5-mortality (19.4/1000 in control
571 villages and 13.5/1000 in intervention areas), although this is likely due to the cumulative effect of the broader package
572 of products, given that ACT uptake did not increase (household survey) [41].

574 Discussion

575 This systematic review synthesises research findings across a wide range of interventions relevant to malaria case
576 management in PMRs in sub-Saharan Africa, providing a holistic view of the evidence base on policy options for retail
577 intervention. We adopted broader study design eligibility criteria than many systematic reviews, including studies with
578 randomised and non-randomised control groups, and those with a baseline but no contemporaneous control. This
579 partly reflected a desire to be as inclusive as possible of available evidence, but also the fact that randomised or even
580 controlled designs may not be feasible or appropriate when evaluating large scale operational implementation of
581 interventions such as AMFm, where distribution through standard supply chains or use of mass media severely limits
582 the potential to restrict interventions to certain areas. We excluded studies that had neither a historical nor a
583 contemporaneous control, though we recognise that uncontrolled cross-sectional studies can provide additional
584 insights, and we draw on some of these in this Discussion. Our review also excludes qualitative research, though we
585 recognise that this is vital for understanding the reasons for intervention (in)effectiveness, and the broader intended
586 and unintended consequences. Geographical coverage of included studies was quite broad, covering urban and rural
587 areas, and 8 countries, though the only evidence from Francophone West and Central Africa was one study covering
588 AMFm in Niger. This may present a barrier in terms of generalisability to the many high malaria burden countries in
589 these regions such as DRC, Mali, Burkina Faso and Cameroon.

590 We summarise here the key findings under each intervention category, and identify the outstanding evidence gaps,
591 before turning to recommendations for future research. Beginning with ACT subsidy programmes and their supporting
592 interventions, there is strong evidence that these increase the market share of quality-assured ACT, with the increase
593 substantial in most settings. This has been demonstrated through both controlled small-scale studies, and the

594 evaluation of AMFm and CPM at national scale in multiple countries. Later studies have indicated that market share
595 gains from AMFm were generally sustained even with lower CPM subsidy levels in most settings. Small-scale studies
596 also provide strong evidence of increased ACT use based on household survey data. For national subsidy programmes
597 household survey data are less complete and not so clear cut, but during AMFm ACT use increases were documented
598 in 3 countries overall and among PMR users in a further one. There is also positive evidence on the equity of ACT
599 subsidy programmes, with benefits experienced in both rural and urban areas, and among poorer groups.

600 A meta-analysis by Morris et al of the impact of ACT subsidies on private sector ACT use provided further support for
601 these conclusions, estimating that each USD 1 decrease in ACT price was linked to a 24 percentage point increase in
602 ACT use in the private sector, with no significant differences in this relationship when comparing the poorest vs richest
603 groups, rural vs urban populations or children vs adults [23]. Other cross-sectional studies not eligible for this review
604 indicate that the coverage of ACT subsidies can vary across groups though this depends on context. Ye et al found that
605 the market share of AMFm-subsidised ACTs in private for-profit outlets was higher in remote than in non-remote areas
606 in Ghana, but lower in remote areas in Kenya [64]. Tougher et al explored the impact by socio-economic group, finding
607 that in Nigeria use of subsidized ACTs from for-profit outlets was concentrated among the rich, while in Uganda it was
608 concentrated among the poor [65].

609 No interventions leading to substantial improvement in user adherence to ACT dosing regimens were identified, with
610 adherence remaining at around two thirds in nearly all studies, indicating the range of factors beyond information that
611 influence user behaviour [66]. RDT provision also did not improve adherence [44, 56].

612 Turning to the literature on RDT and iCCM provision, there are similarities between these two groups of studies,
613 although the iCCM studies are far fewer in number and all from Uganda. For both interventions most studies are small-
614 scale pilots or experiments, with strong internal validity reflecting their individually or cluster randomized designs.
615 However, the interventions often include features not replicable under implementation at large scale, such as
616 providing ACT or RDT for free to PMRs and in some cases to users, direct distribution of commodities to PMRs, or
617 frequent supervision, and in several studies research team staff administering the RDTs (S5 Table). Despite these
618 limitations, one can draw a number of conclusions from this body of evidence. First provision of both RDT and iCCM
619 by PMRs is feasible. Secondly, in two studies under relatively controlled conditions, very high RDT uptake (over 97%)
620 and dispensing by RDT result (over 92%) were found, though these studies relied on data collection methods likely to

621 be subject to substantial Hawthorne effects, such as PMRs' own records or direct observation. In studies under more
622 operational conditions and with methods less subject to Hawthorne bias, rates of RDT uptake of around two thirds
623 were found in some studies, though in others uptake was below 20%. The potential for reductions in price to increase
624 RDT uptake was mixed: reducing prices from high unsubsidised levels (USD 1.5 or above) to below USD 0.4 did
625 stimulate uptake, but demand was relatively insensitive to smaller changes in subsidised prices. High rates of
626 dispensing by RDT result were demonstrated in most relatively operational settings, especially for RDT positive
627 patients where in all but one study over 80% obtained ACT. For RDT negatives, many studies found appropriate
628 dispensing rates over 77%, though in two studies this was under 50%. It was notable that all but one of the studies
629 testing RDTs in PMRs were conducted in moderate to high malaria transmission settings (S3 Table), though one might
630 expect RDT use to be particularly important in curtailing unnecessary ACT use in lower transmission settings. Similar
631 uptake and dispensing results were obtained where CHWs conducted RDTs and provided vouchers for ACT purchase
632 at PMRs [57, 58]. This hybrid approach would only be feasible in settings with a substantial functional and sustainable
633 CHW network, and would require engagement and coordination across a wide range of stakeholders. No evidence was
634 reported on the equity impact of RDT or iCCM introduction.

635 There was wide variation in rates of antibiotic dispensing to febrile patients in RDT and iCCM studies, from close to
636 zero to around a third, despite nearly all antibiotics being prescription-only medicines in most settings [7]. Managing
637 antibiotic use is hampered by the lack of clear guidance on how non-malaria febrile illnesses should be
638 treated/referred by PMRs [10]. In particular, concern has been expressed that introduction of RDTs could lead to
639 antimalarials being substituted by antibiotics for RDT negatives, with overall increases in antibiotic use documented
640 in many public sector settings [63]. Within this review two studies showed little change or a decrease in antibiotic
641 provision [58, 59], while one showed an increase (Mbonye et al, reported in Hopkins 2017 [63]), though it was not
642 possible to assess for which patients antibiotics were warranted.

643 In marked contrast to the ACT subsidy literature, there were no eligible studies on RDT or iCCM implementation at
644 large scale, with the biggest being Maloney et al, covering 2 districts in Tanzania [46]. This reflected a lack of eligible
645 evaluations for some of the larger-scale RDT and iCCM initiatives in sub-Saharan Africa. A prominent example is the
646 USD 20 million UNITAID-funded project to create private sector RDT markets in five African countries between 2013
647 and 2016 [67, 68]. In Kenya, Madagascar and Tanzania the implementing agency procured RDTs and provided a range

648 of services along the supply chain. In Nigeria and Uganda, both RDTs and ancillary services such as training, waste
649 management and demand creation were procured from manufacturers, and delivered through their networks of in-
650 country importers and distributors. The project reportedly led to sales of 1.3-1.6 million RDTs, initiated regulatory
651 change in 3 countries and updated policies on RDT use in all countries, and was argued in the evaluation to have
652 fostered sustainable RDT markets in Kenya, Uganda and Tanzania, though not in Nigeria or Madagascar [67]. The
653 UNITAID-funded team also drew on lessons from their project to produce a “Roadmap for optimizing private sector
654 malaria rapid diagnostic testing” in collaboration with WHO, providing detailed guidance on policy implementation
655 [69]. However, despite numerous data collection activities being undertaken, no evaluation meeting the inclusion
656 criteria for this review was available, partly reflecting a focus on “learning by doing” during implementation, and partly
657 the curtailment of funding before full scale-up. Other sizeable PMR projects without an evaluation eligible for this
658 review include Defeat Malaria in DRC which involved RDT provision through pharmacies; and MalariaCare’s
659 introduction of iCCM in drug shops in Nigeria [16]; while for the similar EQuIPP project in Nigeria, the evaluation is
660 only available in summary form with insufficient methodological detail for inclusion in this review [70].

661 Turning to the broader PMR interventions that covered a wider range of health conditions, the evidence base of
662 eligible studies was very limited, and no evaluations were identified of such interventions involving RDTs. The ADDO
663 programme has been implemented at national scale in Tanzania, with similar projects initiated in Ghana, Uganda and
664 Liberia [71]. However, only two studies were identified with a baseline or control, both in Tanzania, providing some
665 evidence of increased ACT uptake. The Living Goods model of establishing CHWs as retailers did not improve ACT
666 uptake, but did improve the quality of ACTs in the wider market. However, replicability has not been established in
667 other settings, and evidence was not available on more recent versions of the Living Goods model implemented at
668 large scale in Uganda and Kenya.

669 Only one of the evaluations eligible for this review employed any digital or online approaches for training, supervision,
670 monitoring or surveillance of PMRs (Dieci et al used an existing digital sales and inventory management platform to
671 deliver patient subsidies and provider performance incentives [48]). However, multiple digital tools are being
672 developed, tested and implemented by NGOs and private tech companies in Africa, both specific to malaria and with
673 broader remits [72, 73]. These can be classified into three broad groups:

- 674 - PMR-facing – typically mobile app based, these include: (i) Mobile reporting of surveillance data from PMRs e.g.
675 Private Sector Integrated Surveillance System (ISS) piloted in ADDOs, and Uganda’s mTrac tool [74], which both
676 link to DHIS2; (ii) mobile-based detailing and training programmes e.g. PSI COVID training via WhatsApp; (iii)
677 Electronic point-of-sale (e-POS) systems, which provide a platform for PMRs to monitor their stock and support
678 re-ordering, and can also be used to monitor their practices in real-time, offer feedback, provide bulk discounts,
679 deliver training messages, and target subsidies e.g. MaishaMeds (as used by Dieci et al [48]), Bloom, Shelf Life; (iv)
680 digital reading of RDTs that automates reporting of test results e.g. Audere’s HealthPulse; and (v) clinical decision-
681 support tools e.g. THINKMD’s Medsinc, SHOPSPPlus TB STARR, D-Tree International’s Afya-Tek referral platform.
- 682 - Patient-facing – (i) online platforms or apps for generic or targeted health messaging e.g. Viamo, askNivi; (ii) apps
683 or card systems using mobile money to target subsidies to specific users or those testing positive e.g. mPharma’s
684 Mutti card; (iii) digital platforms linked with insurance e.g. Babyl.
- 685 - Regulator/supervisor-facing - tablet-based tools that facilitate in-person supervision or inspection e.g. PSI’s Health
686 Network Quality Improvement System (HNQIS).

687 Such digital tools are likely to be used in most retail interventions going forward, so the lack of evidence on their
688 impact presents a challenge for policy makers, though it is anticipated that more data will be available in the near
689 future. For example, the TESTsmART RCT in Kenya and Nigeria is evaluating conditional ACT subsidies and bonuses to
690 PMR-staff delivered through a mobile app [75].

691 Another challenge in making policy decisions on the evidence base in this review is that ACT and RDT markets have
692 changed considerably since the early phase of the review period, and this could have a substantial impact on
693 intervention effects. Of the interventions involving ACT subsidies with no RDTs, all the sub-national studies began pre-
694 2010, and the baselines for the national AMFm/CPM studies were all pre-2012. These interventions started from a low
695 level of retail ACT sales, and quite high ACT retail prices. For example, in the AMFm countries, the baseline market
696 share of quality-assured ACTs in private-for profit outlets was under 7% in all but one country [12], but in 2018/19 it
697 was 21% in Kenya, 30% in Nigeria and 50% in Uganda [76]. One might therefore expect a quality-assured ACT subsidy
698 programme introduced now to have smaller effects on ACT use than one introduced a decade ago. However, evidence
699 on the growing predominance of non quality-assured ACTs (i.e. not meeting international quality requirements) in
700 retail markets in recent years [77-79], indicates that subsidies could still play a role in increasing the market share of

701 quality-assured medicines. However, this may face resistance from those who fear this would crowd-out local
702 manufacturers who lack the capacity to apply for pre-qualified status [18].

703 In addition to these developments in ACT markets, the policy environment has also changed over the course of the
704 review period, reflecting WHO's advocacy that all suspected malaria cases receive parasitological confirmation before
705 treatment [80]. This means that programmes to subsidise ACT in PMRs are unlikely to be supported without RDT
706 provision. The RDT market in PMRs has also expanded over the review period, though to a much smaller degree than
707 for ACTs. While there has been some increase in in RDT availability, the percentage of PMRs stocking RDTs has
708 remained well below 20% [6, 79], meaning that there is still considerable growth potential. It is likely that users are far
709 more familiar with RDTs than they were in the early period of this review, reflecting their use across the public sector
710 in recent years, which might increase user responsiveness to interventions to enhance RDT provision in PMRs. On the
711 other hand, all but one of the RDT and iCCM interventions included in the review were implemented in the context of
712 subsidized ACTs, and the impact on RDT uptake and dispensing by test result in the absence of ACT subsidies is unclear.

713 In sum, important knowledge gaps remain, and an ongoing programme of evidence generation is needed to inform
714 PMR interventions. We recommend that the research and policy agenda incorporate four key priorities:

715 First, evidence is needed on the impact of large-scale interventions to enhance the use of RDTs in guiding ACT use,
716 covering multiple districts in a range of urban/ rural, francophone/ anglophone, and endemicity settings. Given that
717 costs of ACT subsidies were US\$336 million for AMFm Phase 1 alone [12], it is likely that strategies using much lower
718 commodity subsidies may be required. It is also important to recognise that approaches used in earlier studies such
719 as face-to-face training and supervision of all enrolled PMRs, may not be feasible given the sheer number of such
720 outlets and competing demands on health sector and regulatory staff. Rather these studies should test scalable and
721 affordable models, incorporating "smart" approaches that benefit from substantial economies of scale, such as PMR-
722 facing digital technologies for training, supervision, monitoring, stock control and surveillance; use of mass media; and
723 engagement with trade associations, importers and distributors. While these strategies are unlikely to be amenable
724 to RCT designs, other robust approaches to evaluation would be possible, and it is crucial that funders of such
725 interventions also support the generation and dissemination of this evidence, including the benefits of including the
726 high proportion of malaria cases seen at PMRs in national surveillance systems. Implementing these strategies will
727 require changes in regulation at least for some countries and PMR types. In 2019 of 7 countries surveyed (Chad, DRC,

728 Ghana, Kenya, Nigeria, Tanzania, Uganda) RDTs could be administered in pharmacies in only 4 countries (DRC, Ghana,
729 Nigeria, Uganda), while in registered drug stores in only 3 (Ghana, Nigeria, Uganda) [7]. Although it is recognised that
730 illicit sales are common in some settings where they are not officially permitted [7], the lack of regulatory approval
731 presents challenges for any intervention. However, expansion of point-of-care tests in PMRs for other conditions,
732 including COVID-19, HIV and diabetes, may serve to shift the policy discourse. Similar considerations are relevant for
733 evaluation of scale up of iCCM, which will likely also require adoption of scalable, smart intervention components.

734 Secondly, to enhance sustainability and government buy-in consideration should be given to the potential to integrate
735 malaria and iCCM PMR strategies with broader health system developments, and wider private sector engagement
736 strategies [81]. This may involve linking with PMR programmes for other health conditions such as TB [82] or family
737 planning [83], or engagement with wider initiatives to strengthen PMR regulation and accreditation, medicine and
738 diagnostic test regulation, antimicrobial stewardship, or social health insurance [19]. The limited evidence base on
739 such broader strategies also highlights the necessity for such strategies to be tied to robust evaluation.

740 Thirdly, we propose a set of recommendations for future evaluations. First a standard set of core indicators should be
741 used in all evaluations going forward. Core indicators should include ACT and RDT uptake; dispensing of both
742 antimalarials and antibiotics by test status (positive, negative, no test); and referral according to guidelines. While we
743 recognise that different authors may favour different precise definitions of these indicators, to enhance comparability
744 we propose that all studies at least report the primary outcomes specified for this review (see Methods). Further, we
745 suggest that data from household surveys be broken down by treatment source (presenting for PMRs separately); that
746 metrics for ACTs are presented for both quality-assured and all ACTs; and that ACT and RDT availability and price are
747 also presented where feasible, to help understand the pathways to impact. We also recommend careful consideration
748 of the choice of data collection method; for example while use of routine paper-based PMR records may be lower
749 cost, the Hawthorne effect may lead to substantial over-estimation of study outcomes. Where feasible, we also
750 suggest that evaluators consider including assessment of the accuracy of RDT results performed at PMRs, given that
751 the two studies in this review that conducted study blood slides found discrepancies that could signal significant false
752 positive cases in PMRs [44, 47]. Given the importance of understanding equity of impact, we also recommend
753 measurement of the socio-economic status of users, for example using simplified asset indices [84].

754 Fourthly, to consider the relative value for money of PMR strategies, policy makers require evidence on their predicted
755 cost-effectiveness. However, very few empirical cost and cost-effectiveness analyses of relevant interventions in sub-
756 Saharan Africa exist [48, 85-87]. Going forward, the need to gather additional empirical cost data should be noted,
757 together with the potential to use cost-effectiveness models to estimate outcomes such as the cost per death averted,
758 and explore how these vary with intervention effectiveness and context [88-90].

759

760

761

762 Acknowledgements

763 We are grateful for the advice and review of earlier drafts from Andrea Bosman, Jane Cunningham, Peter Olumese
764 and Nicole Dagata.

765 Funding

766 This review was funded by the Global Malaria Programme of the World Health Organisation.

767 Author Contributions

768 All authors contributed to protocol development. Searches and screening were conducted by ST and TJS; data
769 extraction by ST, TJS and CG; and writing of first draft by CG and ST. All authors contributed to and reviewed the final
770 draft.

771

772 Supporting Information

773 **S1 Table. Search strategy**

774 **S2 Table. Quality assessment checklist**

775 **S3 Table. Study and intervention characteristics**

776 **S4 Table. Study data collection methods**

777 **S5 Table. Quality assessment of included studies**

778 **S6 Table. Heat maps**

779

780 References

- 781 1. World Health Organization. World malaria report 2021. Geneva: World Health Organization, Licence: CC BY-
782 NC-SA 3.0 IGO; 2021.
- 783 2. World Health Organisation. WHO Guidelines for the Treatment of Malaria, 2nd edition. Geneva: World
784 Health Organization; 2010.
- 785 3. WHO. Universal access to malaria diagnostic testing: an operational manual. Geneva: World Health
786 Organisation, <https://apps.who.int/iris/handle/10665/44657> 2011.
- 787 4. World Health Organization. World malaria report 2019. Geneva: World Health Organization, Licence: CC BY-
788 NC-SA 3.0 IGO; 2019.
- 789 5. Bradley SEK, Rosapep L, Shiras T. Where Do Caregivers Take Their Sick Children for Care? An Analysis of Care
790 Seeking and Equity in 24 USAID Priority Countries. *Glob Health Sci Pract.* 2020;8(3):518-33. Epub 20200930. doi:
791 10.9745/GHSP-D-20-00115. PubMed PMID: 33008861; PubMed Central PMCID: PMCPMC7541105.
- 792 6. ACTwatch Group, Hanson K, Goodman C. Testing times: trends in availability, price, and market share of
793 malaria diagnostics in the public and private healthcare sector across eight sub-Saharan African countries from 2009
794 to 2015. *Malar J.* 2017;16(1):205. Epub 20170519. doi: 10.1186/s12936-017-1829-5. PubMed PMID: 28526075;
795 PubMed Central PMCID: PMCPMC5438573.
- 796 7. Khurana TR, Counihan H, Olinga C, Esch K, Okita A, Poyer S, et al. Analysis of policies and regulations that
797 affect malaria case management in the private sector in Chad, Democratic Republic of Congo, Ghana, Nigeria, Kenya,
798 Uganda and United Republic of Tanzania: Working document prepared for the WHO technical consultation on
799 private sector case management of malaria in high burden countries, May 2019; 2019.
- 800 8. ACTwatch Group, Tougher S, Hanson K, Goodman C. What happened to anti-malarial markets after the
801 Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African
802 countries under continuation of the private sector co-payment mechanism. *Malar J.* 2017;16(1):173. Epub 20170425.
803 doi: 10.1186/s12936-017-1814-z. PubMed PMID: 28441956; PubMed Central PMCID: PMCPMC5405529.
- 804 9. World Health Organization. A study on the public health and socioeconomic impact of substandard and
805 falsified medical products. Geneva: World Health Organization, Licence: CC BY-NC-SA 3.0 IGO; 2017.
- 806 10. Hopkins H, Bruxvoort K, Goodman C, Ansah EK, Yeung SM, Clarke S. Technical Brief: Malaria Case
807 Management in the Private Sector, 30 November 2016. Geneva: The Global Fund; 2016.
- 808 11. Goodman C, Brieger W, Unwin A, Mills A, Meek S, Greer G. Medicine sellers and malaria treatment in sub-
809 Saharan Africa: what do they do and how can their practice be improved? Special Issue: Defining and defeating the
810 intolerable burden of malaria III Progress and perspectives. 2007;77(6(Supplement)):203-18.
- 811 12. Tougher S, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, Goodman C, et al. Effect of the Affordable Medicines
812 Facility-malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based
813 combination therapies in seven countries: a before-and-after analysis of outlet survey data. *Lancet (British edition).*
814 2012;380(9857):1916-26. doi: [http://dx.doi.org/10.1016/S0140-6736\(12\)61732-2](http://dx.doi.org/10.1016/S0140-6736(12)61732-2).
- 815 13. Boulton I. Key learnings for malaria programme managers from AMFm Phase I. Geneva: Roll Back Malaria
816 Partnership,; 2013.
- 817 14. Visser T, Bruxvoort K, Maloney K, Leslie T, Barat LM, Allan R, et al. Introducing malaria rapid diagnostic tests
818 in private medicine retail outlets: a systematic literature review. *PLoS ONE.* 2017;12(3):e0173093. doi:
819 <http://dx.doi.org/10.1371/journal.pone.0173093>.
- 820 15. Awor P, Miller J, Peterson S. Systematic literature review of integrated community case management and
821 the private sector in Africa: relevant experiences and potential next steps. Themed Issue: Current scientific evidence
822 for integrated community case management (iCCM) in Africa: findings from the iCCM evidence symposium.
823 2014;4(2):020414.
- 824 16. White J, Wadsworth AC, Clarence C, McCarten-Gibbs M. Case Management of Childhood Illness in the
825 Private Health Sector: A review of models of care and their effectiveness in reducing childhood diarrhea, malaria,
826 and pneumonia. December 2018. . Rockville, MD: Sustaining Health Outcomes through the Private Sector (SHOPS)
827 Plus: Abt Associates Inc.; 2018.
- 828 17. Embrey M, Vialle-Valentin C, Dillip A, Kihyo B, Mwasi R, Semali IA, et al. Understanding the Role of
829 Accredited Drug Dispensing Outlets in Tanzania's Health System. *PLoS One.* 2016;11(11):e0164332. Epub 20161108.
830 doi: 10.1371/journal.pone.0164332. PubMed PMID: 27824876; PubMed Central PMCID: PMCPMC5100953.
- 831 18. World Health Organisation. Meeting report of the WHO technical consultation on malaria case management
832 in the private sector in high-burden countries, 1–3 May 2019, WHO Headquarters, Geneva, Switzerland. Geneva:
833 World Health Organisation, WHO/CDS/GMP/MPAC/2019.12; 2019.

- 834 19. Silverman R, Rosen D, Regan L, Vernon J, Yadav P. Malaria Case Management in the Private Sector in Africa:
835 A Call for Action to Identify Sustainable Solutions, August 2021: Center for Global Development; 2021.
- 836 20. ACTwatch Group, Phok S, Phanalasy S, Thein ST, Likhitsup A. Private sector opportunities and threats to
837 achieving malaria elimination in the Greater Mekong Subregion: results from malaria outlet surveys in Cambodia, the
838 Lao PDR, Myanmar, and Thailand. *Malar J.* 2017;16(1):180. Epub 20170502. doi: 10.1186/s12936-017-1800-5.
839 PubMed PMID: 28464945; PubMed Central PMCID: PMC4977426.
- 840 21. Lussiana C. Towards subsidized malaria rapid diagnostic tests. Lessons learned from programmes to
841 subsidise artemisinin-based combination therapies in the private sector: a review. *Health Policy Plan.*
842 2016;31(7):928-39. Epub 20150409. doi: 10.1093/heapol/czv028. PubMed PMID: 25862732; PubMed Central PMCID:
843 PMC4977424.
- 844 22. Bennett A, Avancena ALV, Wegbreit J, Cotter C, Roberts K, Gosling R. Engaging the private sector in malaria
845 surveillance: a review of strategies and recommendations for elimination settings. *Malaria Journal.* 2017;16(252).
846 doi: <http://dx.doi.org/10.1186/s12936-017-1901-1>.
- 847 23. Morris A, Ward A, Moonen B, Sabot O, Cohen JM. Price subsidies increase the use of private sector ACTs:
848 evidence from a systematic review. *Health Policy Plan.* 2015;30(3):397-405. Epub 20140314. doi:
849 10.1093/heapol/czu013. PubMed PMID: 24633915; PubMed Central PMCID: PMC4353896.
- 850 24. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality
851 both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health.*
852 1998;52(6):377-84. doi: 10.1136/jech.52.6.377. PubMed PMID: 9764259; PubMed Central PMCID:
853 PMC1756728.
- 854 25. Drummond MF, McGuire A. *Economic Evaluation in Health Care - Merging theory with practice.* Oxford:
855 Oxford University Press; 2021.
- 856 26. EPHPP. Quality Assessment tool for Quantitative Studies [https://www.ehpp.ca/quality-assessment-tool-for-](https://www.ehpp.ca/quality-assessment-tool-for-quantitative-studies/)
857 [quantitative-studies/](https://www.ehpp.ca/quality-assessment-tool-for-quantitative-studies/): The Effective Public Health Practice Project.
- 858 27. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for
859 assessing the quality of nonrandomised studies in meta-analyses.
860 https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp: Universities of Newcastle, Australia and Ottawa,
861 Canada.
- 862 28. Kangwana BP, Kedenge SV, Noor AM, Alegana VA, Nyandigisi AJ, Jayesh P, et al. The effect of an anti-malarial
863 subsidy programme on the quality of service provision of artemisinin-based combination therapy in Kenya: a cluster-
864 randomized, controlled trial. *Malaria Journal.* 2013;12(81).
- 865 29. Kangwana BP, Kedenge SV, Noor AM, Alegana VA, Nyandigisi AJ, Pandit J, et al. The impact of retail-sector
866 delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized
867 controlled trial. *PLoS Medicine.* 2011;8(5):e1000437. doi: <http://dx.doi.org/10.1371/journal.pmed.1000437>.
- 868 30. Lussiana C, Floridia M, Rosario JMd, Fortes F, Allan R. Impact of introducing subsidized combination
869 treatment with artemether-lumefantrine on sales of anti-malarial monotherapies: a survey of private sector
870 pharmacies in Huambo, Angola. *Trans R Soc Trop Med Hyg.* 2016;110(10):588-96. doi:
871 <http://dx.doi.org/10.1093/trstmh/trw071>.
- 872 31. Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, Bishop D, et al. Piloting the global subsidy: the impact of
873 subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. *PLoS*
874 *ONE.* 2009;(September):e6857. doi: <http://dx.doi.org/10.1371/journal.pone.0006857>.
- 875 32. Talisuna AO, Daumerie PG, Balyeku A, Egan T, Piot B, Coghlan R, et al. Closing the access barrier for effective
876 antimalarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study.
877 *Malaria Journal.* 2012;11(356).
- 878 33. AMFm Independent Evaluation Team. *Independent Evaluation of Phase 1 of the Affordable Medicines*
879 *Facility - malaria (AMFm), Multi-Country Independent Evaluation Report: Final Report.* Calverton, Maryland and
880 London: ICF International and London School of Hygiene and Tropical Medicine.; 2012.
- 881 34. Fink G, Dickens WT, Jordan M, Cohen JL. Access to subsidized ACT and malaria treatment - evidence from the
882 first year of the AMFm program in six districts in Uganda. *Health Policy Plan.* 2014;29(4):517-27. doi:
883 <http://dx.doi.org/10.1093/heapol/czt041>.
- 884 35. Fiore J. *The Impact of Subsidized Antimalarials on Treatment Seeking Behavior,* Working Paper 1717, March
885 2018: Department of Economics, Tulane University; 2018.
- 886 36. Thomson R, Festo C, Johanes B, Kalolella A, Bruxvoort K, Nchimbi H, et al. Has Tanzania embraced the green
887 leaf? Results from outlet and household surveys before and after implementation of the Affordable Medicines
888 Facility-malaria. *PLoS ONE.* 2014;9(5):e95607. doi: <http://dx.doi.org/10.1371/journal.pone.0095607>.


- 889 37. Bruxvoort K, Festo C, Kalolella A, Cairns M, Lyaruu P, Kenani M, et al. Cluster randomized trial of text
890 message reminders to retail staff in Tanzanian drug shops dispensing artemether-lumefantrine: effect on dispenser
891 knowledge and patient adherence. *Am J Trop Med Hyg.* 2014;91(4):844-53. doi: [http://dx.doi.org/10.4269/ajtmh.14-](http://dx.doi.org/10.4269/ajtmh.14-0126)
892 [0126](http://dx.doi.org/10.4269/ajtmh.14-0126).
- 893 38. Cohen J, Saran I. The impact of packaging and messaging on adherence to malaria treatment: evidence from
894 a randomized controlled trial in Uganda. *Journal of Development Economics.* 2018;134:68-95. doi:
895 <http://dx.doi.org/10.1016/j.jdeveco.2018.04.008>.
- 896 39. Raifman JR, Lanthorn HE, Rokicki S, Fink G. The impact of text message reminders on adherence to
897 antimalarial treatment in northern Ghana: a randomized trial. *PLoS One.* 2014;9(10):e109032. Epub 20141028. doi:
898 10.1371/journal.pone.0109032. PubMed PMID: 25350546; PubMed Central PMCID: PMC4211682.
- 899 40. Björkman Nyqvist M, Svensson J, Yanagizawa-Drott D. Can Good Products Drive Out Bad? A Randomized
900 Intervention in the Antimalarial Medicine Market in Uganda. *Journal of the European Economic Association*
901 2021;20(3):957-1000. doi: <https://doi.org/10.1093/jeea/jvab053>.
- 902 41. Björkman Nyqvist M, Guariso A, Svensson J, Yanagizawa-Drott D. Reducing Child Mortality in the Last Mile:
903 Experimental Evidence on Community Health Promoters in Uganda. *American Economic Journal: Applied Economics.*
904 2019;11(3):155–92. doi: <https://doi.org/10.1257/app.20170201>.
- 905 42. Thomson R, Johanes B, Festo C, Kalolella A, Taylor M, Tougher S, et al. An assessment of the malaria-related
906 knowledge and practices of Tanzania's drug retailers: exploring the impact of drug store accreditation. *BMC Health*
907 *Services Research.* 2018;18(169). doi: <http://dx.doi.org/10.1186/s12913-018-2966-4>.
- 908 43. Briggs MA, Kalolella A, Bruxvoort K, Wiegand R, Lopez G, Festo C, et al. Prevalence of malaria parasitemia
909 and purchase of artemisinin-based combination therapies (ACTs) among drug shop clients in two regions in Tanzania
910 with ACT subsidies. *PLoS ONE.* 2014;9(4):e94074. doi: <http://dx.doi.org/10.1371/journal.pone.0094074>.
- 911 44. Ansah EK, Narh-Bana S, Affran-Bonful H, Bart-Plange C, Cundill B, Gyapong M, et al. The impact of providing
912 rapid diagnostic malaria tests on fever management in the private retail sector in Ghana: a cluster randomized trial.
913 *The BMJ.* 2015;350(H1019).
- 914 45. Cohen J, Fink G, Maloney K, Berg K, Jordan M, Svoronos T, et al. Introducing rapid diagnostic tests for malaria
915 to drug shops in Uganda: a cluster-randomized controlled trial. *Bull World Health Organ.* 2015;93(3):142-51. doi:
916 <http://dx.doi.org/10.2471/BLT.14.142489>.
- 917 46. Maloney K, Ward A, Krenz B, Petty N, Bryson L, Dolkart C, et al. Expanding access to parasite-based malaria
918 diagnosis through retail drug shops in Tanzania: evidence from a randomized trial and implications for treatment.
919 *Malaria Journal.* 2017;16(6). doi: <http://dx.doi.org/10.1186/s12936-016-1658-y>.
- 920 47. Mbonye AK, Magnussen P, Sham L, Hansen KS, Cundill B, Chandler C, et al. A cluster randomised trial
921 introducing rapid diagnostic tests into registered drug shops in Uganda: impact on appropriate treatment of malaria.
922 *PLoS ONE.* 2015;10(7):e0129545. doi: <http://dx.doi.org/10.1371/journal.pone.0129545>.
- 923 48. Dieci M, Gertler P, Kolstad J. Using Patient Versus Provider Incentives to Improve the Diagnosis and
924 Treatment of Malaria: University of California Berkeley, Working Paper, February 27, 2023; 2023.
- 925 49. Omale UI, Azuogu BN, Alo C, Madubueze UC, Oka OU, Okeke KC, et al. Social group and health-care provider
926 interventions to increase the demand for malaria rapid diagnostic tests among community members in Ebonyi State,
927 Nigeria: a cluster-randomised controlled trial. *Lancet Global Health.* 2021;9(3):e320-e30. doi:
928 [http://dx.doi.org/10.1016/S2214-109X\(20\)30508-8](http://dx.doi.org/10.1016/S2214-109X(20)30508-8).
- 929 50. Onwujekwe O, Mangham-Jefferies L, Cundill B, Alexander N, Langham J, Ibe O, et al. Effectiveness of
930 Provider and Community Interventions to Improve Treatment of Uncomplicated Malaria in Nigeria: A Cluster
931 Randomized Controlled Trial. *PLoS One.* 2015;10(8):e0133832. Epub 20150826. doi: 10.1371/journal.pone.0133832.
932 PubMed PMID: 26309023; PubMed Central PMCID: PMC4550271.
- 933 51. Soniran OT, Mensah BA, Cheng NI, Abuaku B, Ahorlu CS. Improved adherence to test, treat, and track (T3)
934 malaria strategy among Over-the-Counter Medicine Sellers (OTCMS) through interventions implemented in selected
935 rural communities of Fanteakwa North district, Ghana. *Malar J.* 2022;21(1):317. Epub 20221105. doi:
936 10.1186/s12936-022-04338-9. PubMed PMID: 36335323; PubMed Central PMCID: PMC9636763.
- 937 52. Cohen J, Dupas P, Schaner S. Price Subsidies, Diagnostic Tests, and Targeting of Malaria Treatment: Evidence
938 from a Randomized Controlled Trial. *Am Econ Rev.* 2015;105(2):609-45.
- 939 53. Ikwuobe JO, Faragher BE, Alawode G, Lalloo DG. The impact of rapid malaria diagnostic tests upon anti-
940 malarial sales in community pharmacies in Gwagwalada, Nigeria. *Malaria Journal.* 2013;12(380).
- 941 54. Laktabai J, Saran I, Zhou Y, Simmons RA, Turner EL, Visser T, et al. Subsidise the test, the treatment or both?
942 Results of an individually randomised controlled trial of the management of suspected malaria fevers in the retail
943 sector in western Kenya. *BMJ Global Health.* 2020;5(11). doi: <http://dx.doi.org/10.1136/bmjgh-2020-003378>.

- 944 55. Modrek S, Schatzkin E, Cruz Adl, Isiguzo C, Nwokolo E, Anyanti J, et al. SMS messages increase adherence to
945 rapid diagnostic test results among malaria patients: results from a pilot study in Nigeria. *Malaria Journal*.
946 2014;13(69).
- 947 56. Saran I, Yavuz E, Kasozi H, Cohen J. Can Rapid Diagnostic Testing for Malaria Increase Adherence to
948 Artemether-Lumefantrine?: A Randomized Controlled Trial in Uganda. *Am J Trop Med Hyg*. 2016;94(4):857-67. Epub
949 20160229. doi: 10.4269/ajtmh.15-0420. PubMed PMID: 26928828; PubMed Central PMCID: PMC4824230.
- 950 57. O'Meara WP, Mohanan M, Laktabai J, Lesser A, Platt A, Maffioli E, et al. Assessing the independent and
951 combined effects of subsidies for antimalarials and rapid diagnostic testing on fever management decisions in the
952 retail sector: results from a factorial randomised trial in western Kenya. *BMJ Global Health*. 2016;1(2):e000101. doi:
953 <http://dx.doi.org/10.1136/bmjgh-2016-000101>.
- 954 58. O'Meara WP, Menya D, Laktabai J, Platt A, Saran I, Maffioli E, et al. Improving rational use of ACTs through
955 diagnosis-dependent subsidies: Evidence from a cluster-randomized controlled trial in western Kenya. *PLoS Med*.
956 2018;15(7):e1002607. Epub 20180717. doi: 10.1371/journal.pmed.1002607. PubMed PMID: 30016316; PubMed
957 Central PMCID: PMC6049880.
- 958 59. Awor P, Wamani H, Tylleskar T, Jagoe G, Peterson S. Increased access to care and appropriateness of
959 treatment at private sector drug shops with integrated management of malaria, pneumonia and diarrhoea: a quasi-
960 experimental study in Uganda. *PLoS ONE*. 2014;9(12):e115440. doi:
961 <http://dx.doi.org/10.1371/journal.pone.0115440>.
- 962 60. Bagonza A, Kitutu FE, Peterson S, Martensson A, Mutto M, Awor P, et al. Effectiveness of peer-supervision on
963 pediatric fever illness treatment among registered private drug sellers in East-Central Uganda: An interrupted time
964 series analysis. *Health Sci Rep*. 2021;4(2):e284. Epub 20210507. doi: 10.1002/hsr2.284. PubMed PMID: 33977166;
965 PubMed Central PMCID: PMC8103081.
- 966 61. Kitutu FE, Kalyango JN, Mayora C, Selling KE, Peterson S, Wamani H. Integrated community case
967 management by drug sellers influences appropriate treatment of paediatric febrile illness in South Western Uganda:
968 a quasi-experimental study. *Malaria Journal*. 2017;16(425). doi: <http://dx.doi.org/10.1186/s12936-017-2072-9>.
- 969 62. Mbonye AK, Buregyeya E, Rutebemberwa E, Lal S, Clarke SE, Hansen KS, et al. Treatment of Sick Children
970 Seeking Care in the Private Health Sector in Uganda: A Cluster Randomized Trial. *Am J Trop Med Hyg*.
971 2020;102(3):658-66. doi: 10.4269/ajtmh.19-0367. PubMed PMID: 31971139; PubMed Central PMCID:
972 PMC7056412.
- 973 63. Hopkins H, Bruxvoort KJ, Cairns ME, Chandler CI, Leurent B, Ansah EK, et al. Impact of introduction of rapid
974 diagnostic tests for malaria on antibiotic prescribing: analysis of observational and randomised studies in public and
975 private healthcare settings. *BMJ*. 2017;356:j1054. Epub 20170329. doi: 10.1136/bmj.j1054. PubMed PMID:
976 28356302; PubMed Central PMCID: PMC5370398.
- 977 64. Ye Y, Arnold F, Noor A, Wamukoya M, Amuasi J, Blay S, et al. The Affordable Medicines Facility-malaria
978 (AMFm): are remote areas benefiting from the intervention? *Malaria Journal*. 2015;14(398).
- 979 65. Tougher S, Hanson K, Goodman CA. Does subsidizing the private for-profit sector benefit the poor? Evidence
980 from national antimalarial subsidies in Nigeria and Uganda. *Health Econ*. 2021;30(10):2510-30. Epub 20210722. doi:
981 10.1002/hec.4386. PubMed PMID: 34291524.
- 982 66. Banek K, DiLiberto DD, Webb EL, Smith SJ, Chandramohan D, Staedke SG. Exploring Barriers and Facilitators
983 of Adherence to Artemisinin-Based Combination Therapies for the Treatment of Uncomplicated Malaria in Children
984 in Freetown, Sierra Leone. *Healthcare (Basel)*. 2021;9(9). Epub 20210918. doi: 10.3390/healthcare9091233. PubMed
985 PMID: 34575007; PubMed Central PMCID: PMC8471195.
- 986 67. Dalberg. Price subsidies increase the use of private sector ACTs: evidence from a systematic review, Final
987 Report2016.
- 988 68. Poyer S, Musuva A, Njoki N, Okara R, Cutherell A, Sievers D, et al. Fever case management at private health
989 facilities and private pharmacies on the Kenyan coast: analysis of data from two rounds of client exit interviews and
990 mystery client visits. *Malaria Journal*. 2018;17(112). doi: <http://dx.doi.org/10.1186/s12936-018-2267-8>.
- 991 69. PSI. A roadmap for optimizing private sector malaria rapid diagnostic testing: Lessons learned from a multi-
992 country pilot project in Africa: Population Services International; 2019.
- 993 70. MCSP. Improving Health Outcomes for Children Under Five in Nigeria, April 2019: Maternal Child Survival
994 Program, USAID; 2019.
- 995 71. Rutta E, Liana J, Embrey M, Johnson K, Kimatta S, Valimba R, et al. Accrediting retail drug shops to
996 strengthen Tanzania's public health system: an ADDO case study. *J Pharm Policy Pract*. 2015;8:23. Epub 20150925.
997 doi: 10.1186/s40545-015-0044-4. PubMed PMID: 26413304; PubMed Central PMCID: PMC4582893.

- 998 72. CHAI. Case Study: Scoping digital solutions for improving quality of care in the informal private sector 2022
999 [24/11/22]. Available from: [https://www.clintonhealthaccess.org/case-study/case-study-scoping-digital-solutions-](https://www.clintonhealthaccess.org/case-study/case-study-scoping-digital-solutions-for-improving-quality-of-care-in-the-informal-private-sector/)
000 [for-improving-quality-of-care-in-the-informal-private-sector/](https://www.clintonhealthaccess.org/case-study/case-study-scoping-digital-solutions-for-improving-quality-of-care-in-the-informal-private-sector/).
- 001 73. Dagata N. Scoping digital solutions for improving quality of care in the informal private sector: Clinton Health
002 Access Initiative; 2021.
- 003 74. CHAI. Case Study: Expanding mTrac to Drug shops and Clinics in Uganda to Strengthen Integrated Malaria
004 Surveillance 2022 [24/11/22]. Available from: [https://www.clintonhealthaccess.org/case-study/case-study-](https://www.clintonhealthaccess.org/case-study/case-study-expanding-mtrac-to-drug-shops-and-clinics-in-uganda-to-strengthen-integrated-malaria-surveillance/)
005 [expanding-mtrac-to-drug-shops-and-clinics-in-uganda-to-strengthen-integrated-malaria-surveillance/](https://www.clintonhealthaccess.org/case-study/case-study-expanding-mtrac-to-drug-shops-and-clinics-in-uganda-to-strengthen-integrated-malaria-surveillance/).
- 006 75. Woolsey AM, Simmons RA, Woldeghebriel M, Zhou Y, Ogunsola O, Laing S, et al. Incentivizing appropriate
007 malaria case management in the private sector: a study protocol for two linked cluster randomized controlled trials
008 to evaluate provider- and client-focused interventions in western Kenya and Lagos, Nigeria. *Implement Sci.*
009 2021;16(1):14. Epub 20210120. doi: 10.1186/s13012-020-01077-w. PubMed PMID: 33472650; PubMed Central
010 PMCID: PMCPCMC7816435.
- 011 76. CHAI. Research Blog Post: Sustaining a functioning market for malaria commodities 2022 [24/02/2023].
012 Available from: [https://www.clintonhealthaccess.org/research/sustaining-a-functioning-market-for-malaria-](https://www.clintonhealthaccess.org/research/sustaining-a-functioning-market-for-malaria-commodities/)
013 [commodities/](https://www.clintonhealthaccess.org/research/sustaining-a-functioning-market-for-malaria-commodities/).
- 014 77. ACTwatch Group, Newton PN, Hanson K, Goodman C. Do anti-malarials in Africa meet quality standards? The
015 market penetration of non quality-assured artemisinin combination therapy in eight African countries. *Malar J.*
016 2017;16(1):204. Epub 20170525. doi: 10.1186/s12936-017-1818-8. PubMed PMID: 28539125; PubMed Central
017 PMCID: PMCPCMC5444102.
- 018 78. Rosen D, Vernon J, Silverman R, Juma E, Dieci M, P. Y. Malaria Case Management After the Affordable
019 Medicines Facility for Malaria (AMFm): Availability, Quality, and Market Share for ACTs in Kenya's Private
020 Pharmacies, Working Paper 561, December 2020. Washington, DC:: Center for Global Development; 2020.
- 021 79. Edwards HM, Sarwar R, Mahmud P, Emmanuel S, Maxwell K, Tibenderana JK. The private sector market for
022 malaria rapid diagnostic tests in Nigeria: results of the 2018 market survey. *Malar J.* 2022;21(1):190. Epub 20220616.
023 doi: 10.1186/s12936-022-04209-3. PubMed PMID: 35710474.
- 024 80. World Health Organisation. Test, treat, track: scaling up diagnostic testing, treatment and surveillance for
025 malaria. Geneva: World Health Organisation; 2012.
- 026 81. World Health Organisation. Engaging the private health service delivery sector through governance in mixed
027 health systems: strategy report of the WHO Advisory Group on the Governance of the Private Sector for Universal
028 Health Coverage. . Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO.; 2020.
- 029 82. World Health Organisation. Public-private mix for TB prevention and care: a roadmap. Licence: CC BY-NC-SA
030 3.0 IGO. Geneva: World Health Organisation. Licence: CC BY-NC-SA 3.0 IGO.; 2018.
- 031 83. Lamba G, Shroff ZC, Babar ZU, Ghaffar A. Drug shops for stronger health systems: learning from initiatives in
032 six LMICs. *J Pharm Policy Pract.* 2021;14(Suppl 1):94. Epub 20211116. doi: 10.1186/s40545-021-00374-z. PubMed
033 PMID: 34784982; PubMed Central PMCID: PMCPCMC8594096.
- 034 84. Chakraborty NM, Fry K, Behl R, Longfield K. Simplified Asset Indices to Measure Wealth and Equity in Health
035 Programs: A Reliability and Validity Analysis Using Survey Data From 16 Countries. *Glob Health Sci Pract.*
036 2016;4(1):141-54. Epub 20160325. doi: 10.9745/GHSP-D-15-00384. PubMed PMID: 27016550; PubMed Central
037 PMCID: PMCPCMC4807755.
- 038 85. Goodman CA, Mutemi WM, Baya EK, Willetts A, Marsh V. The cost-effectiveness of improving malaria home
039 management: shopkeeper training in rural Kenya. *Health Policy Plan.* 2006;21(4):275-88. doi:
040 <http://dx.doi.org/10.1093/heapol/czl011>.
- 041 86. Hansen KS, Clarke SE, Sham L, Magnussen P, Mbonye AK. Cost-effectiveness analysis of introducing malaria
042 diagnostic testing in drug shops: a cluster-randomised trial in Uganda. *PLoS ONE.* 2017;12(12):e0189758. doi:
043 <http://dx.doi.org/10.1371/journal.pone.0189758>.
- 044 87. Lubogo P, Lukyamuzi JE, Kyambadde D, Komakech AA, Kitutu FE, Mulogo EM. Cost-effectiveness analysis of
045 integrated community case management delivery models utilizing drug sellers and community health workers for
046 treatment of under-five febrile cases of malaria, pneumonia, diarrhoea in rural Uganda. *Malar J.* 2021;20(1):407.
047 Epub 20211018. doi: 10.1186/s12936-021-03944-3. PubMed PMID: 34663345; PubMed Central PMCID:
048 PMCPCMC8524984.
- 049 88. Bath D, Goodman C, Yeung S. Modelling the cost-effectiveness of introducing subsidised malaria rapid
050 diagnostic tests in the private retail sector in sub-Saharan Africa. *BMJ Glob Health.* 2020;5(5). doi: 10.1136/bmjgh-
051 2019-002138. PubMed PMID: 32439690; PubMed Central PMCID: PMCPCMC7247415.

- 052 89. Ozawa S, Evans DR, Higgins CR, Laing SK, Awor P. Development of an agent-based model to assess the
053 impact of substandard and falsified anti-malarials: Uganda case study. *Malar J.* 2019;18(1):5. Epub 20190109. doi:
054 10.1186/s12936-018-2628-3. PubMed PMID: 30626380; PubMed Central PMCID: PMC6327614.
- 055 90. Klein EY, Smith DL, Cohen JM, Laxminarayan R. Bioeconomic analysis of child-targeted subsidies for
056 artemisinin combination therapies: a cost-effectiveness analysis. *J R Soc Interface.* 2015;12(107). doi:
057 10.1098/rsif.2014.1356. PubMed PMID: 25994293; PubMed Central PMCID: PMC4590492.

058



Figure